false Q3 0000884624 --12-31 Large Accelerated Filer 0.3333 us-gaap:OtherAssetsNoncurrent us-gaap:PropertyPlantAndEquipmentNet us-gaap:OtherLiabilitiesCurrent us-gaap:OtherLiabilitiesNoncurrent 0000884624 2019-01-01 2019-09-30 xbrli:shares 0000884624 2019-10-25 iso4217:USD 0000884624 2019-09-30 0000884624 2018-12-31 iso4217:USD xbrli:shares 0000884624 2019-07-01 2019-09-30 0000884624 2018-07-01 2018-09-30 0000884624 2018-01-01 2018-09-30 0000884624 us-gaap:CommonStockMember 2018-12-31 0000884624 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000884624 us-gaap:RetainedEarningsMember 2018-12-31 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000884624 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000884624 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-03-31 0000884624 us-gaap:AccountingStandardsUpdate201802Member us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000884624 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000884624 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000884624 2019-01-01 2019-03-31 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000884624 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000884624 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000884624 us-gaap:CommonStockMember 2019-03-31 0000884624 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000884624 us-gaap:RetainedEarningsMember 2019-03-31 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000884624 2019-03-31 0000884624 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000884624 2019-04-01 2019-06-30 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000884624 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000884624 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000884624 us-gaap:CommonStockMember 2019-06-30 0000884624 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000884624 us-gaap:RetainedEarningsMember 2019-06-30 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000884624 2019-06-30 0000884624 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000884624 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000884624 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000884624 us-gaap:CommonStockMember 2019-09-30 0000884624 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000884624 us-gaap:RetainedEarningsMember 2019-09-30 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000884624 us-gaap:CommonStockMember 2017-12-31 0000884624 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000884624 us-gaap:RetainedEarningsMember 2017-12-31 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000884624 2017-12-31 0000884624 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000884624 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-03-31 0000884624 us-gaap:AccountingStandardsUpdate201616Member us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000884624 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 2018-03-31 0000884624 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000884624 2018-01-01 2018-03-31 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000884624 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000884624 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000884624 us-gaap:CommonStockMember 2018-03-31 0000884624 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000884624 us-gaap:RetainedEarningsMember 2018-03-31 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000884624 2018-03-31 0000884624 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000884624 2018-04-01 2018-06-30 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000884624 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000884624 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000884624 us-gaap:CommonStockMember 2018-06-30 0000884624 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000884624 us-gaap:RetainedEarningsMember 2018-06-30 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000884624 2018-06-30 0000884624 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000884624 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000884624 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000884624 us-gaap:CommonStockMember 2018-09-30 0000884624 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000884624 us-gaap:RetainedEarningsMember 2018-09-30 0000884624 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000884624 2018-09-30 0000884624 ofix:SpinalKineticsMember 2019-01-01 2019-09-30 0000884624 ofix:OptionsMedicalLimitedLiabilityCompanyMember 2019-01-01 2019-09-30 0000884624 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-09-30 0000884624 us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-09-30 ofix:Segment 0000884624 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0000884624 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0000884624 ofix:AcquisitionRelatedAmortizationAndRemeasurementExpenseMember 2018-07-01 2018-09-30 0000884624 ofix:AcquisitionRelatedAmortizationAndRemeasurementExpenseMember 2018-01-01 2018-09-30 0000884624 us-gaap:AccountingStandardsUpdate201802Member 2019-01-01 2019-01-01 0000884624 ofix:SpinalKineticsMember 2018-04-30 2018-04-30 0000884624 srt:MaximumMember ofix:SpinalKineticsMember 2018-04-30 0000884624 ofix:SpinalKineticsMember 2018-04-30 0000884624 ofix:DevelopedTechnologyMember ofix:SpinalKineticsMember 2018-04-30 0000884624 us-gaap:InProcessResearchAndDevelopmentMember ofix:SpinalKineticsMember 2018-04-30 0000884624 ofix:TrademarksFiniteLivedMember ofix:SpinalKineticsMember 2018-04-30 0000884624 ofix:DevelopedTechnologyMember ofix:SpinalKineticsMember 2018-04-30 2018-04-30 0000884624 us-gaap:InProcessResearchAndDevelopmentMember ofix:SpinalKineticsMember 2018-04-30 2018-04-30 0000884624 ofix:TrademarksFiniteLivedMember ofix:SpinalKineticsMember 2018-04-30 2018-04-30 0000884624 ofix:GlobalSpineMember ofix:SpinalKineticsMember 2019-02-06 0000884624 ofix:SpinalKineticsMember 2019-07-01 2019-09-30 0000884624 ofix:SpinalKineticsMember 2018-07-01 2018-09-30 0000884624 ofix:SpinalKineticsMember 2018-01-01 2018-09-30 0000884624 2019-01-31 2019-01-31 0000884624 ofix:OptionsMedicalFounderMember 2019-01-31 2019-01-31 xbrli:pure 0000884624 ofix:OptionsMedicalLimitedLiabilityCompanyMember ofix:OperatingLeaseAssetsMember 2019-01-31 0000884624 us-gaap:CustomerRelationshipsMember ofix:OptionsMedicalLimitedLiabilityCompanyMember 2019-01-31 0000884624 ofix:AssembledWorkforceMember ofix:OptionsMedicalLimitedLiabilityCompanyMember 2019-01-31 0000884624 ofix:OptionsMedicalLimitedLiabilityCompanyMember 2019-01-31 0000884624 ofix:OptionsMedicalLimitedLiabilityCompanyMember ofix:ShortTermOperatingLeaseLiabilityMember 2019-01-31 0000884624 ofix:OptionsMedicalLimitedLiabilityCompanyMember ofix:LongTermOperatingLeaseLiabilityMember 2019-01-31 0000884624 us-gaap:CustomerRelationshipsMember ofix:OptionsMedicalLimitedLiabilityCompanyMember 2019-01-31 2019-01-31 0000884624 ofix:AssembledWorkforceMember ofix:OptionsMedicalLimitedLiabilityCompanyMember 2019-01-31 2019-01-31 0000884624 2019-01-01 0000884624 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000884624 us-gaap:AccountingStandardsUpdate201602Member ofix:DifferenceBetweenLeasesGuidanceInEffectBeforeAndAfterTopic842Member 2018-12-31 0000884624 us-gaap:RevolvingCreditFacilityMember ofix:TwoThousandFifteenCreditAgreementMember 2019-01-01 2019-09-30 0000884624 us-gaap:RevolvingCreditFacilityMember ofix:TwoThousandFifteenCreditAgreementMember 2015-08-31 0000884624 us-gaap:RevolvingCreditFacilityMember ofix:TwoThousandFifteenCreditAgreementMember 2019-09-30 0000884624 country:IT 2019-09-30 iso4217:EUR 0000884624 us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember us-gaap:SubsequentEventMember 2019-10-25 0000884624 us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0000884624 us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember us-gaap:SubsequentEventMember 2019-10-28 0000884624 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember us-gaap:SubsequentEventMember 2019-10-25 0000884624 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember srt:MinimumMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0000884624 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0000884624 us-gaap:BaseRateMember us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember srt:MinimumMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0000884624 us-gaap:BaseRateMember us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0000884624 us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember srt:MinimumMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0000884624 us-gaap:RevolvingCreditFacilityMember ofix:SecondAmendedAndRestatedCreditAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2019-10-25 2019-10-25 0000884624 us-gaap:FairValueMeasurementsRecurringMember ofix:TreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member 2019-09-30 0000884624 us-gaap:FairValueMeasurementsRecurringMember ofix:TreasurySecuritiesMember 2019-09-30 0000884624 us-gaap:FairValueMeasurementsRecurringMember ofix:TreasurySecuritiesMember 2018-12-31 0000884624 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member ofix:BoneBiologicsIncMember 2019-09-30 0000884624 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember ofix:BoneBiologicsIncMember 2019-09-30 0000884624 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember ofix:BoneBiologicsIncMember 2018-12-31 0000884624 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember ofix:ENeuraIncMember 2018-12-31 0000884624 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-09-30 0000884624 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2019-09-30 0000884624 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000884624 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000884624 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2019-09-30 0000884624 ofix:BoneBiologicsIncMember ofix:EquityWarrantsMember 2019-01-01 2019-09-30 0000884624 ofix:BoneBiologicsIncMember 2019-06-30 0000884624 ofix:BoneBiologicsIncMember 2018-06-30 0000884624 ofix:BoneBiologicsIncMember 2018-12-31 0000884624 ofix:BoneBiologicsIncMember 2017-12-31 0000884624 us-gaap:AccountingStandardsUpdate201601Member ofix:BoneBiologicsIncMember 2019-07-01 2019-09-30 0000884624 us-gaap:AccountingStandardsUpdate201601Member ofix:BoneBiologicsIncMember 2018-07-01 2018-09-30 0000884624 us-gaap:AccountingStandardsUpdate201601Member ofix:BoneBiologicsIncMember 2019-01-01 2019-09-30 0000884624 us-gaap:AccountingStandardsUpdate201601Member ofix:BoneBiologicsIncMember 2018-01-01 2018-09-30 0000884624 ofix:BoneBiologicsIncMember 2019-07-01 2019-09-30 0000884624 ofix:BoneBiologicsIncMember 2018-07-01 2018-09-30 0000884624 ofix:BoneBiologicsIncMember 2019-01-01 2019-09-30 0000884624 ofix:BoneBiologicsIncMember 2018-01-01 2018-09-30 0000884624 ofix:BoneBiologicsIncMember 2019-09-30 0000884624 ofix:BoneBiologicsIncMember 2018-09-30 0000884624 ofix:ENeuraIncMember ofix:AmendedAndRestatedSeniorSecuredPromissoryNoteMember 2019-01-01 2019-09-30 0000884624 ofix:ENeuraIncMember ofix:AmendedAndRestatedSeniorSecuredPromissoryNoteMember 2019-03-01 0000884624 ofix:ENeuraIncMember ofix:AmendedAndRestatedSeniorSecuredPromissoryNoteMember 2019-03-01 2019-03-01 0000884624 ofix:ENeuraIncMember 2019-07-01 2019-09-30 0000884624 ofix:ENeuraIncMember 2019-09-30 0000884624 ofix:ENeuraIncMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000884624 ofix:ENeuraRestructuredDebtSecurityMember 2019-07-01 2019-09-30 0000884624 ofix:ENeuraRestructuredDebtSecurityMember 2019-01-01 2019-09-30 0000884624 ofix:ENeuraRestructuredDebtSecurityMember 2018-07-01 2018-09-30 0000884624 ofix:ENeuraRestructuredDebtSecurityMember 2018-01-01 2018-09-30 0000884624 us-gaap:FairValueInputsLevel3Member ofix:DebtSecurityAndWarrantMember ofix:ENeuraIncMember 2018-12-31 0000884624 us-gaap:FairValueInputsLevel3Member ofix:DebtSecurityAndWarrantMember ofix:ENeuraIncMember 2017-12-31 0000884624 us-gaap:FairValueInputsLevel3Member ofix:DebtSecurityAndWarrantMember ofix:ENeuraIncMember 2019-01-01 2019-09-30 0000884624 us-gaap:FairValueInputsLevel3Member ofix:DebtSecurityAndWarrantMember ofix:ENeuraIncMember 2018-01-01 2018-09-30 0000884624 us-gaap:FairValueInputsLevel3Member ofix:DebtSecurityAndWarrantMember ofix:ENeuraIncMember 2019-09-30 0000884624 us-gaap:FairValueInputsLevel3Member ofix:DebtSecurityAndWarrantMember ofix:ENeuraIncMember 2018-09-30 0000884624 ofix:SpinalKineticsMember ofix:USFoodAndDrugAdministrationMember 2018-04-30 0000884624 ofix:SpinalKineticsMember ofix:RevenueMilestoneMember 2018-04-30 0000884624 ofix:SpinalKineticsMember ofix:USFoodAndDrugAdministrationMember 2019-02-06 0000884624 ofix:SpinalKineticsMember ofix:USFoodAndDrugAdministrationMember 2019-02-14 2019-02-14 0000884624 ofix:SpinalKineticsMember 2019-09-30 0000884624 ofix:SpinalKineticsMember us-gaap:OtherCurrentLiabilitiesMember 2019-09-30 0000884624 ofix:SpinalKineticsMember us-gaap:OtherNoncurrentLiabilitiesMember 2019-09-30 0000884624 us-gaap:FairValueInputsLevel3Member 2018-12-31 0000884624 us-gaap:FairValueInputsLevel3Member 2018-01-01 2018-09-30 0000884624 us-gaap:FairValueInputsLevel3Member 2019-09-30 0000884624 us-gaap:FairValueInputsLevel3Member 2018-09-30 0000884624 2018-07-31 0000884624 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000884624 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000884624 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember us-gaap:AccountingStandardsUpdate201802Member 2019-01-01 2019-09-30 0000884624 us-gaap:AccountingStandardsUpdate201802Member 2019-01-01 2019-09-30 0000884624 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000884624 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0000884624 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000884624 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000884624 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000884624 ofix:BoneGrowthTherapiesMember 2019-07-01 2019-09-30 0000884624 ofix:BoneGrowthTherapiesMember 2018-07-01 2018-09-30 0000884624 ofix:SpinalImplantsMember 2019-07-01 2019-09-30 0000884624 ofix:SpinalImplantsMember 2018-07-01 2018-09-30 0000884624 ofix:BiologicsMember 2019-07-01 2019-09-30 0000884624 ofix:BiologicsMember 2018-07-01 2018-09-30 0000884624 ofix:GlobalSpineMember 2019-07-01 2019-09-30 0000884624 ofix:GlobalSpineMember 2018-07-01 2018-09-30 0000884624 ofix:GlobalExtremitiesMember 2019-07-01 2019-09-30 0000884624 ofix:GlobalExtremitiesMember 2018-07-01 2018-09-30 0000884624 ofix:BoneGrowthTherapiesMember 2019-01-01 2019-09-30 0000884624 ofix:BoneGrowthTherapiesMember 2018-01-01 2018-09-30 0000884624 ofix:SpinalImplantsMember 2019-01-01 2019-09-30 0000884624 ofix:SpinalImplantsMember 2018-01-01 2018-09-30 0000884624 ofix:BiologicsMember 2019-01-01 2019-09-30 0000884624 ofix:BiologicsMember 2018-01-01 2018-09-30 0000884624 ofix:GlobalSpineMember 2019-01-01 2019-09-30 0000884624 ofix:GlobalSpineMember 2018-01-01 2018-09-30 0000884624 ofix:GlobalExtremitiesMember 2019-01-01 2019-09-30 0000884624 ofix:GlobalExtremitiesMember 2018-01-01 2018-09-30 0000884624 country:PR 2019-06-01 2019-06-30 0000884624 country:PR 2019-06-30 0000884624 us-gaap:OtherAssetsMember 2019-09-30 0000884624 us-gaap:OtherAssetsMember 2018-12-31 0000884624 2018-01-01 2018-12-31 0000884624 ofix:GlobalSpineMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000884624 ofix:GlobalSpineMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0000884624 ofix:GlobalSpineMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000884624 ofix:GlobalSpineMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0000884624 ofix:GlobalExtremitiesMember us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000884624 ofix:GlobalExtremitiesMember us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0000884624 ofix:GlobalExtremitiesMember us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000884624 ofix:GlobalExtremitiesMember us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0000884624 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000884624 us-gaap:CorporateNonSegmentMember 2018-07-01 2018-09-30 0000884624 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0000884624 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-09-30 0000884624 country:US ofix:GlobalSpineMember 2019-07-01 2019-09-30 0000884624 country:US ofix:GlobalSpineMember 2018-07-01 2018-09-30 0000884624 country:US ofix:GlobalSpineMember 2019-01-01 2019-09-30 0000884624 country:US ofix:GlobalSpineMember 2018-01-01 2018-09-30 0000884624 us-gaap:NonUsMember ofix:GlobalSpineMember 2019-07-01 2019-09-30 0000884624 us-gaap:NonUsMember ofix:GlobalSpineMember 2018-07-01 2018-09-30 0000884624 us-gaap:NonUsMember ofix:GlobalSpineMember 2019-01-01 2019-09-30 0000884624 us-gaap:NonUsMember ofix:GlobalSpineMember 2018-01-01 2018-09-30 0000884624 country:US ofix:GlobalExtremitiesMember 2019-07-01 2019-09-30 0000884624 country:US ofix:GlobalExtremitiesMember 2018-07-01 2018-09-30 0000884624 country:US ofix:GlobalExtremitiesMember 2019-01-01 2019-09-30 0000884624 country:US ofix:GlobalExtremitiesMember 2018-01-01 2018-09-30 0000884624 us-gaap:NonUsMember ofix:GlobalExtremitiesMember 2019-07-01 2019-09-30 0000884624 us-gaap:NonUsMember ofix:GlobalExtremitiesMember 2018-07-01 2018-09-30 0000884624 us-gaap:NonUsMember ofix:GlobalExtremitiesMember 2019-01-01 2019-09-30 0000884624 us-gaap:NonUsMember ofix:GlobalExtremitiesMember 2018-01-01 2018-09-30 0000884624 country:US 2019-07-01 2019-09-30 0000884624 country:US 2018-07-01 2018-09-30 0000884624 country:US 2019-01-01 2019-09-30 0000884624 country:US 2018-01-01 2018-09-30 0000884624 us-gaap:NonUsMember 2019-07-01 2019-09-30 0000884624 us-gaap:NonUsMember 2018-07-01 2018-09-30 0000884624 us-gaap:NonUsMember 2019-01-01 2019-09-30 0000884624 us-gaap:NonUsMember 2018-01-01 2018-09-30 0000884624 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000884624 us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0000884624 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000884624 us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0000884624 us-gaap:SellingAndMarketingExpenseMember 2019-07-01 2019-09-30 0000884624 us-gaap:SellingAndMarketingExpenseMember 2018-07-01 2018-09-30 0000884624 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-09-30 0000884624 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-09-30 0000884624 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0000884624 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0000884624 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0000884624 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0000884624 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000884624 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0000884624 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000884624 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0000884624 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000884624 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0000884624 ofix:TimeBasedRestrictedStockAwardsAndUnitsMember 2019-07-01 2019-09-30 0000884624 ofix:TimeBasedRestrictedStockAwardsAndUnitsMember 2018-07-01 2018-09-30 0000884624 ofix:TimeBasedRestrictedStockAwardsAndUnitsMember 2019-01-01 2019-09-30 0000884624 ofix:TimeBasedRestrictedStockAwardsAndUnitsMember 2018-01-01 2018-09-30 0000884624 ofix:PerformanceBasedRestrictedStockAwardsAndUnitsMember 2018-07-01 2018-09-30 0000884624 ofix:PerformanceBasedRestrictedStockAwardsAndUnitsMember 2018-01-01 2018-09-30 0000884624 ofix:MarketBasedRestrictedStockUnitMember 2019-07-01 2019-09-30 0000884624 ofix:MarketBasedRestrictedStockUnitMember 2018-07-01 2018-09-30 0000884624 ofix:MarketBasedRestrictedStockUnitMember 2019-01-01 2019-09-30 0000884624 ofix:MarketBasedRestrictedStockUnitMember 2018-01-01 2018-09-30 0000884624 us-gaap:EmployeeStockMember 2019-07-01 2019-09-30 0000884624 us-gaap:EmployeeStockMember 2018-07-01 2018-09-30 0000884624 us-gaap:EmployeeStockMember 2019-01-01 2019-09-30 0000884624 us-gaap:EmployeeStockMember 2018-01-01 2018-09-30 0000884624 ofix:GlobalSpineMember ofix:InducementGrantsMember ofix:EmploymentAgreementMember 2019-08-05 2019-08-05 0000884624 ofix:PresidentAndChiefExecutiveOfficerMember ofix:RetirementAgreementMember 2019-07-01 2019-09-30 0000884624 ofix:PresidentAndChiefExecutiveOfficerMember ofix:RetirementAgreementMember 2019-01-01 2019-09-30 0000884624 ofix:RetirementAgreementMember 2019-01-01 2019-09-30 0000884624 ofix:RetirementAgreementMember srt:MaximumMember 2019-01-01 2019-09-30 0000884624 srt:MinimumMember 2019-09-30 0000884624 srt:MaximumMember 2019-09-30 0000884624 us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-03-31 0000884624 ofix:StockOptionsAndEmployeeStockPurchasePlanMember 2018-01-01 2018-09-30 0000884624 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0000884624 us-gaap:EmployeeStockOptionMember us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0000884624 us-gaap:EmployeeStockOptionMember us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0000884624 us-gaap:EmployeeStockOptionMember us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0000884624 us-gaap:EmployeeStockOptionMember us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark one)

☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

OR

☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 0-19961

ORTHOFIX MEDICAL INC.

(Exact name of registrant as specified in its charter)

Delaware |  | 98-1340767
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
3451 Plano Parkway, Lewisville, Texas |  | 75056
(Address of principal executive offices) |  | (Zip Code)

(214) 937-2000

(Registrant’s telephone number, including area code)

Not applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated filer | ☒ | Accelerated filer | ☐
Non-Accelerated filer | ☐ | Smaller Reporting Company | ☐
|  | Emerging Growth Company | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

As of October 25, 2019, 19,055,154 shares of common stock were issued and outstanding.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common stock, $0.10 par value per share |  | OFIX |  | Nasdaq Global Select Market

Table of Contents

|  |  |  | Page
PART I |  | FINANCIAL INFORMATION |  |
Item 1. |  | Financial Statements |  | 4
|  | Condensed Consolidated Balance Sheets as of September 30, 2019, and December 31, 2018 |  | 4
|  | Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September 30, 2019, and 2018 |  | 5
|  | Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three and nine months ended September 30, 2019 and 2018 |  | 6
|  | Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2019 and 2018 |  | 7
|  | Notes to the Unaudited Condensed Consolidated Financial Statements |  | 8
Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 23
Item 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  | 33
Item 4. |  | Controls and Procedures |  | 33
PART II |  | OTHER INFORMATION |  |
Item 1. |  | Legal Proceedings |  | 34
Item 1A. |  | Risk Factors |  | 34
Item 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 34
Item 3. |  | Defaults Upon Senior Securities |  | 34
Item 4. |  | Mine Safety Disclosures |  | 34
Item 5. |  | Other Information |  | 34
Item 6. |  | Exhibits |  | 35
SIGNATURES |  | 36

2

Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“the Exchange Act”), and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” or “continue” or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”) and other Securities and Exchange Commission (“SEC”) filings. Therefore, our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to further update any such statement, or the risk factors described in the 2018 Form 10-K and other SEC filings, to reflect new information, the occurrence of future events or circumstances or otherwise.

Trademarks

Solely for convenience, our trademarks and trade names in this report are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that we will not assert, to the fullest extent under applicable law, our rights thereto.

3

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

ORTHOFIX MEDICAL INC.

Condensed Consolidated Balance Sheets

(U.S. Dollars, in thousands, except share data) |  | September 30, 2019 |  |  | December 31, 2018 |
|  | (Unaudited) |  |  |  |  |
Assets |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 56,849 |  |  | $ | 69,623 |
Restricted cash |  |  | 654 |  |  |  | 2,566 |
Trade accounts receivable, net of allowances of $4,073 and $7,463, respectively |  |  | 79,690 |  |  |  | 77,747 |
Inventories |  |  | 80,993 |  |  |  | 76,847 |
Prepaid expenses and other current assets |  |  | 19,617 |  |  |  | 17,856 |
Total current assets |  |  | 237,803 |  |  |  | 244,639 |
Property, plant and equipment, net |  |  | 62,964 |  |  |  | 42,835 |
Intangible assets, net |  |  | 53,613 |  |  |  | 51,897 |
Goodwill |  |  | 71,177 |  |  |  | 72,401 |
Deferred income taxes |  |  | 39,626 |  |  |  | 33,228 |
Other long-term assets |  |  | 10,420 |  |  |  | 21,641 |
Total assets |  | $ | 475,603 |  |  | $ | 466,641 |
Liabilities and shareholders’ equity |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |
Accounts payable |  | $ | 17,892 |  |  | $ | 17,989 |
Current portion of finance lease liability |  |  | 293 |  |  |  | — |
Other current liabilities |  |  | 70,323 |  |  |  | 67,919 |
Total current liabilities |  |  | 88,508 |  |  |  | 85,908 |
Long-term portion of finance lease liability |  |  | 20,767 |  |  |  | — |
Other long-term liabilities |  |  | 59,894 |  |  |  | 45,336 |
Total liabilities |  |  | 169,169 |  |  |  | 131,244 |
Contingencies (Note 8) |  |  |  |  |  |  |  |
Shareholders’ equity |  |  |  |  |  |  |  |
Common shares $0.10 par value; 50,000,000 shares authorized; 18,875,184 and 18,579,688 issued and outstanding as of September 30, 2019 and December 31, 2018, respectively |  |  | 1,888 |  |  |  | 1,858 |
Additional paid-in capital |  |  | 263,064 |  |  |  | 243,165 |
Retained earnings |  |  | 46,063 |  |  |  | 87,078 |
Accumulated other comprehensive income (loss) |  |  | (4,581 | ) |  |  | 3,296 |
Total shareholders’ equity |  |  | 306,434 |  |  |  | 335,397 |
Total liabilities and shareholders’ equity |  | $ | 475,603 |  |  | $ | 466,641 |

The accompanying notes form an integral part of these condensed consolidated financial statements

4

ORTHOFIX MEDICAL INC.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(Unaudited, U.S. Dollars, in thousands, except share and per share data) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Net sales |  | $ | 113,499 |  |  | $ | 111,708 |  |  | $ | 338,461 |  |  | $ | 331,964 |
Cost of sales |  |  | 24,896 |  |  |  | 24,020 |  |  |  | 74,416 |  |  |  | 71,002 |
Gross profit |  |  | 88,603 |  |  |  | 87,688 |  |  |  | 264,045 |  |  |  | 260,962 |
Sales and marketing |  |  | 54,805 |  |  |  | 49,898 |  |  |  | 165,363 |  |  |  | 151,695 |
General and administrative |  |  | 21,090 |  |  |  | 22,276 |  |  |  | 63,497 |  |  |  | 63,658 |
Research and development |  |  | 7,982 |  |  |  | 9,598 |  |  |  | 26,191 |  |  |  | 24,426 |
Acquisition-related amortization and remeasurement (Note 12) |  |  | 23,608 |  |  |  | 2,009 |  |  |  | 31,873 |  |  |  | 3,491 |
Operating income (loss) |  |  | (18,882 | ) |  |  | 3,907 |  |  |  | (22,879 | ) |  |  | 17,692 |
Interest income (expense), net |  |  | 186 |  |  |  | (181 | ) |  |  | 386 |  |  |  | (615 | )
Other expense, net |  |  | (8,146 | ) |  |  | (5,054 | ) |  |  | (8,786 | ) |  |  | (5,785 | )
Income (loss) before income taxes |  |  | (26,842 | ) |  |  | (1,328 | ) |  |  | (31,279 | ) |  |  | 11,292 |
Income tax benefit (expense) |  |  | (13,656 | ) |  |  | 117 |  |  |  | (8,869 | ) |  |  | (6,352 | )
Net income (loss) |  | $ | (40,498 | ) |  | $ | (1,211 | ) |  | $ | (40,148 | ) |  | $ | 4,940 |
Net income (loss) per common share: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  | $ | (2.14 | ) |  | $ | (0.07 | ) |  | $ | (2.13 | ) |  | $ | 0.26 |
Diluted |  |  | (2.14 | ) |  |  | (0.07 | ) |  |  | (2.13 | ) |  |  | 0.26 |
Weighted average number of common shares: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basic |  |  | 18,957,876 |  |  |  | 18,562,204 |  |  |  | 18,847,728 |  |  |  | 18,460,848 |
Diluted |  |  | 18,957,876 |  |  |  | 18,562,204 |  |  |  | 18,847,728 |  |  |  | 18,864,169 |
Other comprehensive income (loss), before tax |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unrealized gain (loss) on debt security |  |  | — |  |  |  | 1,240 |  |  |  | (2,593 | ) |  |  | 3,200 |
Reclassification adjustment for amortization of historical unrealized gains on debt security |  |  | (345 | ) |  |  | — |  |  |  | (1,034 | ) |  |  | — |
Reclassification adjustment for other-than-temporary impairment on debt security |  |  | (5,193 | ) |  |  | — |  |  |  | (5,193 | ) |  |  | — |
Currency translation adjustment |  |  | (1,893 | ) |  |  | (844 | ) |  |  | (2,195 | ) |  |  | (1,322 | )
Other comprehensive income (loss) before tax |  |  | (7,431 | ) |  |  | 396 |  |  |  | (11,015 | ) |  |  | 1,878 |
Income tax related to other comprehensive income (loss) |  |  | 1,388 |  |  |  | (366 | ) |  |  | 2,200 |  |  |  | (798 | )
Other comprehensive income (loss), net of tax |  |  | (6,043 | ) |  |  | 30 |  |  |  | (8,815 | ) |  |  | 1,080 |
Comprehensive income (loss) |  | $ | (46,541 | ) |  | $ | (1,181 | ) |  | $ | (48,963 | ) |  | $ | 6,020 |

The accompanying notes form an integral part of these condensed consolidated financial statements

5

ORTHOFIX MEDICAL INC.

Condensed Consolidated Statements of Changes in Shareholders’ Equity

(Unaudited, U.S. Dollars, in thousands, except share data) |  | Number of Common Shares Outstanding |  |  | Common Shares |  |  | Additional Paid-in Capital |  |  | Retained Earnings |  |  | Accumulated Other Comprehensive Income (Loss) |  |  | Total Shareholders’ Equity |
At December 31, 2018 |  |  | 18,579,688 |  |  | $ | 1,858 |  |  | $ | 243,165 |  |  | $ | 87,078 |  |  | $ | 3,296 |  |  | $ | 335,397 |
Cumulative effect adjustment from adoption of ASU 2016-02 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 71 |  |  |  | — |  |  |  | 71 |
Cumulative effect adjustment from adoption of ASU 2018-02 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (938 | ) |  |  | 938 |  |  |  | — |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 897 |  |  |  | — |  |  |  | 897 |
Other comprehensive loss, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (2,401 | ) |  |  | (2,401 | )
Share-based compensation |  |  | — |  |  |  | — |  |  |  | 5,685 |  |  |  | — |  |  |  | — |  |  |  | 5,685 |
Common shares issued, net |  |  | 211,081 |  |  |  | 21 |  |  |  | 4,012 |  |  |  | — |  |  |  | — |  |  |  | 4,033 |
At March 31, 2019 |  |  | 18,790,769 |  |  | $ | 1,879 |  |  | $ | 252,862 |  |  | $ | 87,108 |  |  | $ | 1,833 |  |  | $ | 343,682 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (547 | ) |  |  | — |  |  |  | (547 | )
Other comprehensive loss, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (371 | ) |  |  | (371 | )
Share-based compensation |  |  | — |  |  |  | — |  |  |  | 5,849 |  |  |  | — |  |  |  | — |  |  |  | 5,849 |
Common shares issued, net |  |  | 40,812 |  |  |  | 4 |  |  |  | (823 | ) |  |  | — |  |  |  | — |  |  |  | (819 | )
At June 30, 2019 |  |  | 18,831,581 |  |  | $ | 1,883 |  |  | $ | 257,888 |  |  | $ | 86,561 |  |  | $ | 1,462 |  |  | $ | 347,794 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (40,498 | ) |  |  | — |  |  |  | (40,498 | )
Other comprehensive loss, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (6,043 | ) |  |  | (6,043 | )
Share-based compensation |  |  | — |  |  |  | — |  |  |  | 5,844 |  |  |  | — |  |  |  | — |  |  |  | 5,844 |
Common shares issued, net |  |  | 43,603 |  |  |  | 5 |  |  |  | (668 | ) |  |  | — |  |  |  | — |  |  |  | (663 | )
At September 30, 2019 |  |  | 18,875,184 |  |  | $ | 1,888 |  |  | $ | 263,064 |  |  | $ | 46,063 |  |  | $ | (4,581 | ) |  | $ | 306,434 |

(Unaudited, U.S. Dollars, in thousands, except share data) |  | Number of Common Shares Outstanding |  |  | Common Shares |  |  | Additional Paid-in Capital |  |  | Retained Earnings |  |  | Accumulated Other Comprehensive Income |  |  | Total Shareholders’ Equity |
At December 31, 2017 |  |  | 18,278,833 |  |  | $ | 1,828 |  |  | $ | 220,591 |  |  | $ | 70,402 |  |  | $ | 3,787 |  |  | $ | 296,608 |
Cumulative effect adjustment from adoption of ASU 2014-09 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 4,761 |  |  |  | — |  |  |  | 4,761 |
Cumulative effect adjustment from adoption of ASU 2016-16 |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,896 | ) |  |  | — |  |  |  | (1,896 | )
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 5,226 |  |  |  | — |  |  |  | 5,226 |
Other comprehensive income, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 697 |  |  |  | 697 |
Share-based compensation |  |  | — |  |  |  | — |  |  |  | 3,916 |  |  |  | — |  |  |  | — |  |  |  | 3,916 |
Common shares issued, net |  |  | 126,511 |  |  |  | 13 |  |  |  | 3,849 |  |  |  | — |  |  |  | — |  |  |  | 3,862 |
At March 31, 2018 |  |  | 18,405,344 |  |  | $ | 1,841 |  |  | $ | 228,356 |  |  | $ | 78,493 |  |  | $ | 4,484 |  |  | $ | 313,174 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 925 |  |  |  | — |  |  |  | 925 |
Other comprehensive income, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 353 |  |  |  | 353 |
Share-based compensation |  |  | — |  |  |  | — |  |  |  | 5,215 |  |  |  | — |  |  |  | — |  |  |  | 5,215 |
Common shares issued, net |  |  | 80,444 |  |  |  | 8 |  |  |  | 171 |  |  |  | — |  |  |  | — |  |  |  | 179 |
At June 30, 2018 |  |  | 18,485,788 |  |  | $ | 1,849 |  |  | $ | 233,742 |  |  | $ | 79,418 |  |  | $ | 4,837 |  |  | $ | 319,846 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,211 | ) |  |  | — |  |  |  | (1,211 | )
Other comprehensive income, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 30 |  |  |  | 30 |
Share-based compensation |  |  | — |  |  |  | — |  |  |  | 5,261 |  |  |  | — |  |  |  | — |  |  |  | 5,261 |
Common shares issued, net |  |  | 50,928 |  |  |  | 5 |  |  |  | (581 | ) |  |  | — |  |  |  | — |  |  |  | (576 | )
At September 30, 2018 |  |  | 18,536,716 |  |  | $ | 1,854 |  |  | $ | 238,422 |  |  | $ | 78,207 |  |  | $ | 4,867 |  |  | $ | 323,350 |

The accompanying notes form an integral part of these condensed consolidated financial statements

6

ORTHOFIX MEDICAL INC.

Condensed Consolidated Statements of Cash Flows

|  | Nine Months Ended September 30, |
(Unaudited, U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |
Cash flows from operating activities |  |  |  |  |  |  |  |
Net income (loss) |  | $ | (40,148 | ) |  | $ | 4,940 |
Adjustments to reconcile net income to net cash from operating activities |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 18,180 |  |  |  | 13,661 |
Amortization of operating lease assets, debt costs and other assets |  |  | 2,724 |  |  |  | 818 |
Provision for doubtful accounts |  |  | 861 |  |  |  | (571 | )
Deferred income taxes |  |  | (3,309 | ) |  |  | (5,082 | )
Share-based compensation |  |  | 17,378 |  |  |  | 14,392 |
Interest and loss on valuation of investment securities |  |  | 5,000 |  |  |  | 3,050 |
Change in fair value of contingent consideration |  |  | 28,140 |  |  |  | 2,689 |
Other |  |  | 1,307 |  |  |  | 1,040 |
Changes in operating assets and liabilities, net of effects of acquisitions |  |  |  |  |  |  |  |
Accounts receivable |  |  | (3,298 | ) |  |  | (225 | )
Inventories |  |  | (4,995 | ) |  |  | 6,880 |
Prepaid expenses and other current assets |  |  | 1,637 |  |  |  | 1,498 |
Accounts payable |  |  | 447 |  |  |  | (2,788 | )
Other current liabilities |  |  | 347 |  |  |  | (13,130 | )
Payment of contingent consideration |  |  | (1,340 | ) |  |  | — |
Other long-term assets and liabilities |  |  | (2,841 | ) |  |  | 1,657 |
Net cash from operating activities |  |  | 20,090 |  |  |  | 28,829 |
Cash flows from investing activities |  |  |  |  |  |  |  |
Acquisition of business, net of cash acquired |  |  | — |  |  |  | (43,749 | )
Capital expenditures for property, plant and equipment |  |  | (13,737 | ) |  |  | (9,586 | )
Capital expenditures for intangible assets |  |  | (1,144 | ) |  |  | (1,138 | )
Asset acquisitions and other investments |  |  | (6,400 | ) |  |  | (1,448 | )
Net cash from investing activities |  |  | (21,281 | ) |  |  | (55,921 | )
Cash flows from financing activities |  |  |  |  |  |  |  |
Proceeds from issuance of common shares |  |  | 6,821 |  |  |  | 5,866 |
Payments related to withholdings for share-based compensation |  |  | (4,271 | ) |  |  | (2,402 | )
Payment of contingent consideration |  |  | (13,660 | ) |  |  | — |
Payments related to finance lease obligation |  |  | (276 | ) |  |  | — |
Other financing activities |  |  | (1,224 | ) |  |  | (476 | )
Net cash from financing activities |  |  | (12,610 | ) |  |  | 2,988 |
Effect of exchange rate changes on cash |  |  | (885 | ) |  |  | (811 | )
Net change in cash, cash equivalents, and restricted cash |  |  | (14,686 | ) |  |  | (24,915 | )
Cash, cash equivalents, and restricted cash at the beginning of period |  |  | 72,189 |  |  |  | 81,157 |
Cash, cash equivalents, and restricted cash at the end of period |  | $ | 57,503 |  |  | $ | 56,242 |
Components of cash, cash equivalents and restricted cash at the end of period |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 56,849 |  |  | $ | 53,783 |
Restricted cash |  |  | 654 |  |  |  | 2,459 |
Cash, cash equivalents, and restricted cash at the end of period |  | $ | 57,503 |  |  | $ | 56,242 |
Supplemental Disclosure of Cash Flow Information: |  |  |  |  |  |  |  |
Noncash investing activities: |  |  |  |  |  |  |  |
Purchase of intangible assets |  | $ | — |  |  | $ | 1,581 |
Contingent consideration recognized at acquisition date |  |  | — |  |  |  | 25,491 |

The accompanying notes form an integral part of these condensed consolidated financial statements

7

ORTHOFIX MEDICAL INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

1. Business and basis of presentation

Orthofix Medical Inc., together with its subsidiaries (the “Company” or “Orthofix”) is a global medical device company focused on musculoskeletal products and therapies. Headquartered in Lewisville, Texas, the Company has two reporting segments: Global Spine and Global Extremities.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair statement have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Form 10-K for the year ended December 31, 2018. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for other interim periods or the year ending December 31, 2019.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition; contractual allowances; allowance for doubtful accounts; inventories; valuation of intangible assets; goodwill; fair value measurements, including contingent consideration; litigation and contingent liabilities; tax matters; and share-based compensation. Actual results could differ from these estimates.

Prior period reclassifications

Certain amortization expense related to intangible assets previously reported in general and administrative expenses has been reclassified to acquisition-related amortization and remeasurement based on use of the underlying intangible asset. This reclassification resulted in decreases to general and administrative expenses of $0.4 million and $0.8 million for the three and nine months ended September 30, 2018, respectively, and increases in acquisition related amortization and remeasurement expense of $0.4 million and $0.8 million for the three and nine months ended September 30, 2018, respectively.

Change in Reporting Segments

The Company has changed its reportable business segments beginning with the first quarter of 2019, to align with changes in how the Company manages its business, reviews operating performance and allocates resources. The Company now reports results under two reportable segments: Global Spine and Global Extremities, and measures operating performance of these two reportable segments based on earnings before interest, tax, depreciation, and amortization (“EBITDA”). For additional discussion regarding segments, see Note 11.

2. Recently adopted accounting standards and recently issued accounting pronouncements

Adoption of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842)

In February 2016 the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, which changes how lessees account for leases. For most leases, a liability will be recorded on the balance sheet based on the present value of future lease obligations with a corresponding right-of-use asset. For leases classified as operating leases, the Company will recognize lease costs on a straight-line basis based on the combined amortization of the lease obligation and the right-of-use asset. Other leases will be accounted for as finance leases similar to capital leases under the previous accounting standard. Effective January 1, 2019, the Company adopted ASU 2016-02 using a modified retrospective approach. Upon adoption, the Company elected a package of practical expedients permitted within the new standard. The practical expedients adopted allow the Company to carry forward its historical lease classification and to not separate and allocate the consideration paid between lease and non-lease components included within a contract. The Company also adopted an optional transition method that waives the requirement to apply the ASU to the comparative periods presented within the financial statements in the year of adoption. Therefore, results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be

8

reported in accordance with the Company’s historic accounting policies under Topic 840. See Note 5 for additional discussion of the Co mpany’s adoption of Topic 842 and its lease accounting policies.

Adoption of ASU 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income

In February 2018, the FASB issued ASU 2018-02, which allows entities to reclassify from accumulated other comprehensive income to retained earnings stranded tax effects resulting from the Tax Cuts and Jobs Act (the "Tax Act"). The Company adopted this guidance effective January 1, 2019, which resulted in an increase to accumulated other comprehensive income and a decrease in retained earnings of $0.9 million.

Other recently adopted accounting guidance

In August 2018, the Securities and Exchange Commission (the “SEC” or the “Commission”) issued SEC Final Rule Release No. 33-10532, Disclosure Update and Simplification, which amends certain of the Commission’s disclosure requirements that have become redundant, duplicative, overlapping, outdated, or superseded, in light of other Commission disclosure requirements, U.S. GAAP, or changes in the information environment. However, in certain instances, the amendments expanded disclosure requirements, including those related to interim disclosures about changes in shareholders’ equity. As amended in the final rule, registrants must now analyze changes in shareholders’ equity, in the form of a reconciliation for the current year-to-date interim periods, with subtotals for each interim period. The Company adopted Release No. 33-10532 during the first quarter of 2019, which resulted in changes in shareholders’ equity presented within the Condensed Consolidated Statements of Changes in Shareholders’ Equity.

Recently issued accounting pronouncements

Topic |  | Description of Guidance |  | Effective Date |  | Status of Company's Evaluation
Financial Instruments - Credit Losses (ASU 2016-13), and subsequent amendments |  | Requires that credit losses for certain types of financial instruments be estimated based on expected losses and also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Applied using a modified retrospective approach, with early adoption permitted. |  | January 1, 2020 |  | The Company has formed an implementation team to evaluate the impact this ASU will have on its consolidated financial statements. Based on the Company's preliminary evaluation, the ASU is expected to primarily impact trade accounts receivable; however, the Company is continuing to evaluate the impact this ASU may have on its consolidated financial statements.
Goodwill (ASU 2017-04) |  | Eliminates Step 2 of the current goodwill impairment test, which requires a hypothetical purchase price allocation to measure goodwill impairment. A goodwill impairment loss will instead be measured at the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the recorded amount of goodwill. Applied on a prospective basis, with early adoption permitted. |  | January 1, 2020 |  | The Company is currently evaluating the impact this ASU may have on its consolidated financial statements. However, the Company does not expect this ASU to have a significant impact on its financial statements or disclosures.
Fair value measurement (ASU 2018-13) |  | Eliminates such disclosures as the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy and adds new disclosure requirements for Level 3 measurements. Certain of the provisions are to be applied retrospectively with other provisions applied prospectively. |  | January 1, 2020 |  | The Company is currently evaluating the impact this ASU may have on its consolidated financial statements. However, the Company does not expect this ASU to have a significant impact on its financial statements but may have significant impact on disclosures for any level 3 assets or liabilities.

9

Topic |  | Description of Guidance |  | Effective Date |  | Status of Company's Evaluation
Implementation costs in a cloud computing arrangement that is a service contract (ASU 2018-15) |  | Aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The accounting for the service element of a hosting arrangement that is a service contract is not affected by the amendments in this update. Applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. |  | January 1, 2020 |  | The Company plans to adopt this ASU prospectively to all implementation costs incurred after the date of adoption and is currently evaluating the impact this ASU may have on its consolidated financial statements. However, the Company does not expect this ASU to have a material impact to its consolidated financial statements.

3. Acquisitions

Acquisition of Spinal Kinetics Inc.

On April 30, 2018, the Company completed the acquisition of Spinal Kinetics Inc. (“Spinal Kinetics”), a privately held developer and manufacturer of artificial cervical and lumbar discs for $45.0 million in net cash, subject to certain adjustments, plus potential milestone payments of up to $60.0 million in cash. The acquisition date fair value of the consideration transferred was $76.6 million. The results of operations for Spinal Kinetics have been included in the Company’s financial results since the acquisition date, April 30, 2018. For additional discussion regarding the valuation of the contingent consideration, see Note 7.

The following table summarizes the fair values of assets acquired and liabilities assumed at the acquisition date:

(U.S. Dollars, in thousands) |  | Final Acquisition Date Fair Value |  |  | Assigned Useful Life
Assets acquired |  |  |  |  |  |
Cash and cash equivalents |  | $ | 6,785 |  |  |
Restricted cash |  |  | 30 |  |  |
Accounts receivable |  |  | 1,705 |  |  |
Inventories |  |  | 8,175 |  |  |
Prepaid expenses and other current assets |  |  | 315 |  |  |
Property, plant and equipment |  |  | 2,285 |  |  |
Other long-term assets |  |  | 320 |  |  |
Developed technology |  |  | 12,400 |  |  | 10 years
In-process research and development ("IPR&D") |  |  | 26,800 |  |  | 10 years
Tradename |  |  | 100 |  |  | 2 years
Deferred income taxes |  |  | 3,594 |  |  |
Total identifiable assets acquired |  | $ | 62,509 |  |  |
Liabilities assumed |  |  |  |  |  |
Accounts payable |  | $ | 351 |  |  |
Other current liabilities |  |  | 2,869 |  |  |
Other long-term liabilities |  |  | 301 |  |  |
Total liabilities assumed |  | $ | 3,521 |  |  |
Goodwill |  |  | 17,612 |  |  |
Total fair value of consideration transferred |  | $ | 76,600 |  |  |

On February 6, 2019, the Company obtained U.S. Food and Drug Administration (“FDA”) approval of the M6-C artificial cervical disc for patients suffering from cervical disease degeneration and started amortizing IPR&D. The $17.6 million of goodwill recognized was assigned to the Global Spine reporting segment.

10

The Company did not recognize any acquisition related costs during the three and nine months ended September 30, 2019 and recorded $0.3 million and $3.3 million of acquisition related costs during the three and nine months ended September 30, 2018. These costs are included in the condensed consolidated statements of operations and comprehensive income (loss) within general and administrative expenses. The Company’s results of operations included net sales of $4.2 million and $2.9 million related to Spinal Kinetics for the three months ended September 30, 2019 and 2018, respectively, and net sales of $10.5 million and $5.2 million for the nine months ended September 30, 2019 and 2018, respectively. Additionally, the Company’s results of operations included net losses of $2.9 million and $2.1 million related to Spinal Kinetics for the three months ended September 30, 2019 and 2018, respectively, and net losses of $10.3 million and $3.5 million for the nine months ended September 30, 2019 and 2018, respectively.

The following table presents the unaudited pro forma results for the three and nine months ended September 30, 2019 and 2018, which combines the historical results of operations of Orthofix and Spinal Kinetics as though the companies had been combined as of January 1, 2018. The unaudited pro forma information is presented for informational purposes only and is not indicative of the results of operations that would have been achieved if the acquisition had taken place at such time.

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
|  | (unaudited) |  |  | (unaudited) |  |  | (unaudited) |  |  | (unaudited) |
Net sales |  | $ | 113,499 |  |  | $ | 111,708 |  |  | $ | 338,461 |  |  | $ | 336,882 |
Net income (loss) |  |  | (40,498 | ) |  |  | (923 | ) |  |  | (40,148 | ) |  |  | 5,276 |

Options Medical, LLC Asset Acquisition

On January 31, 2019, the Company acquired certain assets of Options Medical, LLC (“Options Medical”), a medical device distributor based in Florida. Under the terms of the acquisition, the parties agreed to terminate an existing exclusive sales representative agreement, employees of Options Medical became employees of the Company, and the Company acquired all customer lists and customer information related to the sale of the Company’s products. As consideration for the assets acquired, the Company paid $6.4 million. Additionally, as an inducement to enter into employment with the Company, the Company provided 25,478 restricted stock units (“RSUs”), with a fair value of $1.4 million, to the Options Medical founder. These RSUs will vest in one-third annual increments beginning on the first anniversary of the grant date and are contingent upon continued employment. The following table summarizes the fair values of assets acquired and liabilities assumed at the acquisition date.

(U.S. Dollars, in thousands) |  | Fair Value |  |  | Balance Sheet Classification |  | Assigned Useful Life
Assets acquired |  |  |  |  |  |  |  |
Operating lease assets |  | $ | 175 |  |  | Other long-term assets |  |
Customer relationships |  |  | 5,832 |  |  | Intangible assets, net |  | 10 years
Assembled workforce |  |  | 568 |  |  | Intangible assets, net |  | 5 years
Total identifiable assets acquired |  | $ | 6,575 |  |  |  |  |
Liabilities assumed |  |  |  |  |  |  |  |
Operating lease liability - short-term |  | $ | 69 |  |  | Other current liabilities |  |
Operating lease liability - long-term |  |  | 106 |  |  | Other long-term liabilities |  |
Total liabilities assumed |  |  | 175 |  |  |  |  |
Total fair value of consideration transferred |  | $ | 6,400 |  |  |  |  |

11

4. Inventories

Inventories were as follows:

(U.S. Dollars, in thousands) |  | September 30, 2019 |  |  | December 31, 2018 |
Raw materials |  | $ | 7,760 |  |  | $ | 8,463 |
Work-in-process |  |  | 10,532 |  |  |  | 13,478 |
Finished products |  |  | 62,701 |  |  |  | 54,906 |
Inventories |  | $ | 80,993 |  |  | $ | 76,847 |

5. Leases

As discussed in Note 2, the Company adopted ASU No. 2016-02—Leases (Topic 842), as of January 1, 2019, using the modified retrospective approach. Adoption of the new standard resulted in the recognition of operating lease assets and lease liabilities of $20.2 million and $20.5 million, respectively, as of January 1, 2019. The difference between the lease assets and lease liabilities, net of the deferred tax impact, and the elimination of historical prepaid or deferred rent, was recorded as an adjustment to retained earnings. The net impact of adoption to the Company’s balance sheet as of January 1, 2019 is presented in the table below. The standard did not have a material impact to the Company’s condensed consolidated statements of operations and comprehensive income (loss) or cash flows.

(U.S. Dollars, in thousands) |  | December 31, 2018 |  |  | Impact of Adoption of ASC 842 |  |  | January 1, 2019 |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |  |  |  |  |
Cash, cash equivalents, and restricted cash |  | $ | 72,189 |  |  | $ | — |  |  | $ | 72,189 |
Accounts receivable, net |  |  | 77,747 |  |  |  | — |  |  |  | 77,747 |
Inventories |  |  | 76,847 |  |  |  | — |  |  |  | 76,847 |
Prepaid expenses and other current assets |  |  | 17,856 |  |  |  | (15 | ) |  |  | 17,841 |
Total current assets |  |  | 244,639 |  |  |  | (15 | ) |  |  | 244,624 |
Property, plant, and equipment, net |  |  | 42,835 |  |  |  | — |  |  |  | 42,835 |
Intangible assets, net and goodwill |  |  | 124,298 |  |  |  | — |  |  |  | 124,298 |
Deferred income taxes |  |  | 33,228 |  |  |  | 71 |  |  |  | 33,299 |
Other long-term assets |  |  | 21,641 |  |  |  | 20,209 |  |  |  | 41,850 |
Total assets |  | $ | 466,641 |  |  | $ | 20,265 |  |  | $ | 486,906 |
Liabilities and shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |  |  |  |  |
Accounts payable |  | $ | 17,989 |  |  | $ | — |  |  | $ | 17,989 |
Other current liabilities |  |  | 67,919 |  |  |  | 2,166 |  |  |  | 70,085 |
Total current liabilities |  |  | 85,908 |  |  |  | 2,166 |  |  |  | 88,074 |
Other long-term liabilities |  |  | 45,336 |  |  |  | 18,028 |  |  |  | 63,364 |
Total liabilities |  | $ | 131,244 |  |  | $ | 20,194 |  |  | $ | 151,438 |
Shareholders’ equity |  |  |  |  |  |  |  |  |  |  |  |
Common shares |  |  | 1,858 |  |  |  | — |  |  |  | 1,858 |
Additional paid-in capital |  |  | 243,165 |  |  |  | — |  |  |  | 243,165 |
Retained earnings |  |  | 87,078 |  |  |  | 71 |  |  |  | 87,149 |
Accumulated other comprehensive income |  |  | 3,296 |  |  |  | — |  |  |  | 3,296 |
Total shareholders’ equity |  |  | 335,397 |  |  |  | 71 |  |  |  | 335,468 |
Total liabilities and shareholders’ equity |  | $ | 466,641 |  |  | $ | 20,265 |  |  | $ | 486,906 |

12

The Company determines if an arrangement is a lease at inception. The Company’s leases primarily relate to facilities, vehicles, and equipment. Lease assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities r epresent the obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rat e, the Company’s incremental borrowing rate is used as a discount rate, based on the information available at the commencement date, in determining the present value of lease payments. Lease assets also include the impact of any prepayments made and are re duced by impact of any lease incentives.

The Company has made an accounting policy election for short-term leases, in that the Company will not recognize a lease liability or lease asset on the balance sheet for leases with a lease term of twelve months or less as of the commencement date. Rather, any short-term lease payments will be recognized as an expense on a straight-line basis over the lease term. The current period short-term lease expense reasonably reflects our short-term lease commitments.

The Company has made a policy election for all classifications of leases to combine lease and nonlease components and to account for them as a single lease component. Variable lease payments are excluded from the lease liability and recognized in the period in which the obligation is incurred. Additionally, lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option.

During the first quarter of 2019, the Company entered into an amendment for its corporate headquarters lease. As a result, the classification of this lease changed from an operating lease to a finance lease, resulting in an increase to both the lease liability and lease asset of approximately $8.0 million.

A summary of the Company’s lease portfolio as of September 30, 2019 is presented in the table below:

(U.S. Dollars, in thousands, except lease term and discount rate) |  | Classification |  | September 30, 2019 |
Assets |  |  |  |  |  |
Operating leases |  | Other long-term assets |  | $ | 5,894 |
Finance leases |  | Property, plant and equipment, net |  |  | 20,451 |
Total lease assets |  |  |  |  | 26,345 |
Liabilities |  |  |  |  |  |
Current |  |  |  |  |  |
Operating leases |  | Other current liabilities |  |  | 1,798 |
Finance leases |  | Current portion of finance lease liability |  |  | 293 |
Long-term |  |  |  |  |  |
Operating leases |  | Other long-term liabilities |  |  | 4,205 |
Finance leases |  | Long-term portion of finance lease liability |  |  | 20,767 |
Total lease liabilities |  |  |  | $ | 27,063 |
Weighted Average Remaining Lease Term |  |  |  |  |  |
Operating leases |  |  |  | 4.3 years |
Finance leases |  |  |  | 20.9 years |
Weighted Average Discount Rate |  |  |  |  |  |
Operating leases |  |  |  |  | 2.45 | %
Finance leases |  |  |  |  | 4.38 | %

13

The components of lease costs were as follows:

(U.S. Dollars, in thousands) |  | Three Months ended September 30, 2019 |  |  | Nine Months Ended September 30, 2019 |
Finance lease costs: |  |  |  |  |  |  |  |
Amortization of right-of-use assets |  | $ | 244 |  |  | $ | 728 |
Interest on finance lease liabilities |  |  | 233 |  |  |  | 687 |
Operating lease costs |  |  | 538 |  |  |  | 1,618 |
Short-term lease costs |  |  | 61 |  |  |  | 195 |
Variable lease costs |  |  | 173 |  |  |  | 501 |
Total lease costs |  | $ | 1,249 |  |  | $ | 3,729 |

Supplemental cash flow information related to leases was as follows:

(U.S. Dollars, in thousands) |  | Nine Months Ended September 30, 2019 |
Cash paid for amounts included in the measurement of lease liabilities |  |  |  |
Operating cash flows from operating leases |  | $ | 3,037 |
Operating cash flows from finance leases |  |  | 687 |
Financing cash flows from finance leases |  |  | 276 |
Right-of-use assets obtained in exchange for lease obligations |  |  |  |
Operating leases |  |  | 598 |
Finance leases |  |  | 21,179 |

A summary of the Company’s remaining lease liabilities as of September 30, 2019 is included below:

(U.S. Dollars, in thousands) |  | Operating Leases |  |  | Finance Leases |
2019 |  | $ | 505 |  |  | $ | 321 |
2020 |  | $ | 1,863 |  |  | $ | 1,013 |
2021 |  | $ | 1,654 |  |  | $ | 1,414 |
2022 |  | $ | 1,333 |  |  | $ | 1,442 |
2023 |  | $ | 250 |  |  | $ | 1,471 |
Thereafter |  | $ | 782 |  |  | $ | 27,207 |
Total undiscounted value of lease liabilities |  | $ | 6,387 |  |  | $ | 32,868 |
Less: Interest |  |  | (384 | ) |  |  | (11,808 | )
Present value of lease liabilities |  | $ | 6,003 |  |  | $ | 21,060 |
Current portion of lease liabilities |  |  | 1,798 |  |  |  | 293 |
Long-term portion of lease liabilities |  |  | 4,205 |  |  |  | 20,767 |
Total lease liabilities |  | $ | 6,003 |  |  | $ | 21,060 |

6. Long-term debt

As of September 30, 2019, the Company had no borrowings under its five year $125 million secured revolving credit facility. In addition, the Company had no borrowings on its €5.5 million ($6.0 million) available lines of credit in Italy as of September 30, 2019. The Company was in compliance with all required financial covenants as of September 30, 2019.

On October 25, 2019, the Company, and certain of its wholly-owned subsidiaries (collectively with the Company, the “Borrowers”), as borrowers, and certain material subsidiaries of the Company as guarantors, entered into a Second Amended and Restated Credit Agreement (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a $300 million secured revolving credit facility maturing on October 25, 2024 (the “Facility”), and amends and restates the previous $125 million secured revolving credit facility. As of October 28, 2019, the Borrowers have not made any borrowings under the Amended Credit Agreement.

14

Borrowings under the Amended Credit Agreement may be used for, among other things, working capital and other general corporate purposes of the Company and its subsidiaries (including permitted acquisitions and permitted payments of dividends and other distributions). The Facility is available in US Dollars with up to $150 million of the Facility available to be borrowed in Euros and Pounds Sterling (the “Agreed Currencies”). The Facility further permits up to $50 million to be utilized for the issuance of letters of credit in the Agreed Currencies. The Borrowers have the ability to increase the amount of the Facility, which increases may take the form of increases to the revolving credit commitments or the issuance of new term A loans, by an aggregate amount of up to the greater of $150 million or an incremental amount such that the total amount of the Facility does not exceed 350% of consolidated EBITDA of the Company (as determined for the four fiscal quarter period most recently ended for which financial statements are available), upon satisfaction of customary conditions precedent for such increases or incremental loans and receipt of additional commitments by one or more existing or new lenders.

Borrowings under the Facility bear interest at a floating rate, which will be, at the Borrowers’ option, either LIBOR plus an applicable margin ranging from 1.25% to 2.25%, or a base rate plus an applicable margin ranging from 0.25% to 1.25% (in each case subject to adjustment based on the Company’s total net leverage ratio). An unused fee ranging from 0.15% to 0.25% (subject to adjustment based on the Company’s total net leverage ratio) is payable quarterly in arrears based on the daily amount of the undrawn portion of each lender’s revolving credit commitments under the Facility. Fees are payable on outstanding letters of credit at a rate equal to the applicable margin for LIBOR loans, plus certain customary fees payable solely to the issuer of the letter of credit.

Certain of the Company’s existing and future material subsidiaries (collectively, the “Guarantors”) are required to guarantee the repayment of the Borrowers’ obligations under the Amended Credit Agreement. The obligations of the Borrowers and each of the Guarantors with respect to the Amended Credit Agreement are secured by a pledge of substantially all of the personal property assets of the Borrowers and each of the Guarantors, including accounts receivables, deposit accounts, intellectual property, investment property, inventory, equipment and equity interests in their respective subsidiaries.

The Amended Credit Agreement contains customary affirmative and negative covenants, including limitations on the Company’s and its subsidiaries ability to incur additional debt, grant or permit additional liens, make investments and acquisitions, merge or consolidate with others, dispose of assets, pay dividends and distributions, pay subordinated indebtedness and enter into affiliate transactions. In addition, the Amended Credit Agreement contains financial covenants requiring the Company on a consolidated basis to maintain, as of the last day of any fiscal quarter, a total net leverage ratio of not more than 3.5 to 1.0 (which ratio can be permitted to increase to 4.0 to 1.0 for no more than 4 fiscal quarters following a material acquisition) and an interest coverage ratio of at least 3.0 to 1.0. The Amended Credit Agreement also includes events of default customary for facilities of this type and upon the occurrence of such events of default, subject to customary cure rights, all outstanding loans under the Facility may be accelerated and/or the lenders’ commitments terminated.

7. Fair value measurements and investments

The fair value of the Company’s financial assets and liabilities measured on a recurring basis were as follows:

|  | September 30, 2019 |  |  | December 31, 2018 |
(U.S. Dollars, in thousands) |  | Level 1 |  |  | Level 2 |  |  | Level 3 |  |  | Total |  |  | Total |
Assets |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Treasury securities |  | $ | 447 |  |  | $ | — |  |  | $ | — |  |  | $ | 447 |  |  | $ | 490 |
Bone Biologics equity warrants |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Bone Biologics equity securities |  |  | — |  |  |  | 219 |  |  |  | — |  |  |  | 219 |  |  |  | 219 |
eNeura debt security |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 17,820 |
eNeura warrant |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Total |  | $ | 447 |  |  | $ | 219 |  |  | $ | — |  |  | $ | 666 |  |  | $ | 18,529 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  | $ | — |  |  | $ | — |  |  | $ | (41,700 | ) |  | $ | (41,700 | ) |  | $ | (28,560 | )
Deferred compensation plan |  |  | — |  |  |  | (1,242 | ) |  |  | — |  |  |  | (1,242 | ) |  |  | (1,275 | )
Total |  | $ | — |  |  | $ | (1,242 | ) |  | $ | (41,700 | ) |  | $ | (42,942 | ) |  | $ | (29,835 | )

15

Bone Biologics Equity Warrants and Securities

The Company holds investments in common stock and warrants to purchase shares of common stock of Bone Biologics, Inc. (“Bone Biologics”). The Company’s common stock investments are recorded within other long-term assets while the warrants are considered to have a fair value of zero. The equity securities are considered investments that do not have readily determinable fair values. As such, the Company measures these investments at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Bone Biologics equity securities and warrants beginning balance |  | $ | 219 |  |  | $ | 4,668 |  |  | $ | 219 |  |  | $ | 2,768 |
Impact of adoption of ASU 2016-01 recognized in other income (expense), net |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 1,629 |
Purchase of additional common stock |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 500 |
Fair value adjustments, expirations, and impairments recognized in other income (expense), net |  |  | — |  |  |  | (4,449 | ) |  |  | — |  |  |  | (4,678 | )
Bone Biologics equity securities and warrants ending balance |  | $ | 219 |  |  | $ | 219 |  |  | $ | 219 |  |  | $ | 219 |

eNeura Debt Security and Warrant

As of September 30, 2019, the Company held a debt security of eNeura, Inc. (“eNeura”), a privately held medical technology company that is developing devices for the treatment of migraines. The debt security was originally set to mature on March 4, 2019. On March 1, 2019, the Company entered into an Amended and Restated Senior Secured Promissory Note with eNeura (the “Restructured Debt Security”) to restructure the debt security, which extended the maturity date to the earlier of (i) March 4, 2022, (ii) the effective date of a change in control, or (iii) the effective date of an initial public offering by eNeura, and which also eliminated the conversion feature included within the original note. As consideration for the extension, eNeura issued to the Company a Warrant to Purchase Common Stock (the “Warrant”), exercisable at $0.01 per share over a ten year contractual term, for a number of shares equal to 10% of the sum of the outstanding principal and accrued interest on the Amended and Restated Debt Security as of March 1, 2019, divided by $1.00 (subject to certain anti-dilution provisions).

Prior to the restructuring on March 1, 2019, the debt security was accounted for as an available for sale debt security at fair value and included within other long-term assets. The fair value was based upon significant unobservable inputs, including the use of a discounted cash flow model and assumptions regarding the expected payback period for the debt security, requiring the Company to develop its own assumptions; therefore, the Company had categorized this asset as a Level 3 financial asset.

Subsequent to the restructuring, the debt security was no longer classified as an available for sale debt security, but rather as a held to maturity debt security. The debt security was reclassified from an available for sale debt security to a held to maturity debt security at its fair value on the date of the restructuring. As a result, the unrealized gains included in accumulated other comprehensive income related to the debt security were to be subsequently amortized to interest income over the remaining term of the Restructured Debt Security.

The Warrant was recorded at fair value and included in other long-term assets. The fair value of the Warrant was based on significant unobservable inputs, including the use of a discounted cash flow model and an option-pricing model, requiring the Company to develop its own assumptions; therefore, the Company categorized this asset as a Level 3 financial asset. The Warrant was considered an investment that does not have a readily determinable fair value. As such, the Company measured the Warrant at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.

During the quarter ended September 30, 2019, the Company engaged in negotiations with eNeura to settle the Restructured Debt Security and on October 25, 2019, the Company and eNeura settled the Restructured Debt Security for a $4.0 million cash payment and agreed to transfer the Warrant to eNeura. As such, at September 30, 2019, the Company determined the Restructured Debt Security and Warrant were impaired and adjusted the carrying value of the Restructured Debt Security to $4.0 million, its settlement value, by recording a net other-than-temporary impairment of $6.5 million in other expense, net, which includes a reclassification of the related unrealized gains included in accumulated other comprehensive income of $5.2 million. Further, the Company also reclassified the remaining balance of the Restructured Debt Security to other current assets as payment was received within the next twelve months.

16

During the three and nine months ended September 30, 2019, the Company recognized $0.5 and $1.5 million in interest income related to the eNeura debt security. The Company did not recognize any interest income during the three and nine months ended September 30, 2018.

The following table provides a reconciliation of the beginning and ending balances for the eNeura debt security and Warrant measured and reflected in the condensed consolidated balance sheets at fair value using significant unobservable inputs (Level 3) prior to the settlement discussed above:

(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |
eNeura debt security and Warrant at January 1 |  | $ | 17,820 |  |  | $ | 16,050 |
Gains or losses recorded for the period |  |  |  |  |  |  |  |
Recognized in other comprehensive income (loss) |  |  | (2,593 | ) |  |  | 3,200 |
Change in classification of debt security to held to maturity |  |  | (15,227 | ) |  |  | — |
Issuance of Warrant as consideration for extension |  |  | 491 |  |  |  | — |
Impairment of Warrant |  |  | (491 | ) |  |  | — |
eNeura debt security and Warrant at September 30 |  | $ | — |  |  | $ | 19,250 |

Contingent Consideration

The contingent consideration at the acquisition date of Spinal Kinetics consisted of potential future milestone payments of up to $60.0 million in cash. The milestone payments included (i) up to $15.0 million if the FDA grants approval of Spinal Kinetics’ M6-C artificial cervical disc (the “FDA Milestone”) and (ii) revenue-based milestone payments of up to $45.0 million in connection with future sales of the M6-C artificial cervical disc and the M6-L artificial lumbar disc. Milestones must be achieved within five years of April 30, 2018 to trigger applicable payments.

On February 6, 2019, the Company obtained FDA approval of the M6-C artificial cervical disc. This approval triggered the Company’s payment obligation of $15.0 million for the achievement of the FDA Milestone and such obligation was paid on February 14, 2019. The estimated fair value of the remaining contingent consideration was $41.7 million as of September 30, 2019; however, the actual amount ultimately paid could be higher or lower than the fair value of the remaining contingent consideration. This resulted in the recognition of expense of $22.3 and $28.1 million during the three and nine months ended September 30, 2019, respectively, which was primarily attributable to a change in management’s forecast of future net sales of the artificial discs, including an acceleration of the expected timing of such future sales during the three months ended September 30, 2019, subsequent to the Company’s launch of the product in the U.S. At September 30, 2019, the Company has classified $14.5 million of the liability attributable to the revenue-based milestones within other current liabilities, as the Company expects to pay one of the revenue-based milestones in the next twelve months, and the remaining $27.2 million within other long-term liabilities. Any changes in fair value are recorded as an operating expense and included within acquisition-related amortization and remeasurement.

The Company estimated the fair value of the remaining potential future revenue-based milestone payments using a Monte Carlo simulation. This fair value measurement is based on significant inputs that are unobservable in the market, and thus represents a Level 3 measurement. The key assumptions in applying the Monte Carlo valuation model include the Company’s forecasted future revenues for Spinal Kinetics products, discount rate applied, and assumptions for potential volatility of the Company’s forecasted revenue. Significant changes in these assumptions could result in a significantly higher or lower fair value.

The following table provides a reconciliation of the beginning and ending balances for the contingent consideration measured at fair value using significant unobservable inputs (Level 3):

(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |
Contingent consideration at January 1 |  | $ | 28,560 |  |  | $ | — |
Acquisition date fair value |  |  | — |  |  |  | 25,491 |
Increase in fair value recognized in acquisition-related amortization and remeasurement |  |  | 28,140 |  |  |  | 2,689 |
Payment made |  |  | (15,000 | ) |  |  | — |
Contingent consideration at September 30 |  | $ | 41,700 |  |  | $ | 28,180 |

17

8. Contingencies

In addition to the matters described below, in the normal course of its business, the Company is involved in various lawsuits from time to time and may be subject to certain other contingencies. The Company believes any losses related to these matters are individually and collectively immaterial as to a possible loss and range of loss.

Italian Medical Device Payback (“IMDP”)

In 2015, the Italian Parliament introduced rules for entities that supply goods and services to the Italian National Healthcare System. This healthcare law is expected to impact the business and financial reporting of companies operating in the medical technology sector that sell medical devices in Italy. A key provision of the law is a ‘payback’ measure, requiring companies selling medical devices in Italy to make payments to the Italian government if medical device expenditures exceed regional maximum ceilings. Companies are required to make payments equal to a percentage of expenditures exceeding maximum regional caps. There is considerable uncertainty about how the law will operate and what the exact timeline is for finalization. The Company’s current assessment of the IMDP involves significant judgment regarding the expected scope and actual implementation terms of the measure as the latter have not been clarified to date by Italian authorities. The Company accounts for the estimated cost of the IMDP as sales and marketing expense and recorded expense of $0.3 million and $0.2 million for the three months ended September 30, 2019 and 2018, respectively, and $1.0 million and $0.8 million for the nine months ended September 30, 2019 and 2018, respectively. As of September 30, 2019, the Company has accrued $4.5 million related to the IMDP, which it has classified within other long-term liabilities; however, the actual liability could be higher or lower than the amount accrued once the law has been clarified by the Italian authorities.

Brazil

In July 2018, the Federal Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority inspected the offices of more than 30 companies, including the Company’s office in São Paulo, as part of an investigation into tender irregularities in the medical device industry. Before doing so, the authorities obtained a court order affecting the Company’s (and other companies’) local bank accounts resulting in the freezing of approximately $2.5 million of the Company’s cash, which the Company reclassified to restricted cash. On April 3, 2019, the Company’s appeal regarding the freezing of its local bank accounts was heard by the Brazil Federal Court of Appeals of Rio de Janeiro, in which the Court ordered the unfreezing of the Company’s cash. The cash was then returned without any restrictions in April 2019. As such, this balance was reclassified to cash and cash equivalents during the second quarter of 2019.

In September 2019, in relation to an ongoing legal dispute with a former Brazilian distributor, approximately $0.7 million of the Company’s cash in Brazil was frozen upon request to satisfy a judgment. Although the Company is appealing the judgment, this cash has been reclassified to restricted cash. As of September 30, 2019, the Company has an accrual of $1.6 million related to this matter.

9. Accumulated other comprehensive income (loss)

The components of and changes in accumulated other comprehensive income were as follows:

(U.S. Dollars, in thousands) |  | Currency Translation Adjustments |  |  | Debt Security |  |  | Accumulated Other Comprehensive Income (Loss) |
Balance at December 31, 2018 |  | $ | (2,386 | ) |  | $ | 5,682 |  |  | $ | 3,296 |
Cumulative effect adjustment from adoption of ASU 2018-02 |  |  | — |  |  |  | 938 |  |  |  | 938 |
Other comprehensive loss |  |  | (2,195 | ) |  |  | (2,593 | ) |  |  | (4,788 | )
Income taxes |  |  | — |  |  |  | 641 |  |  |  | 641 |
Reclassification adjustment to: |  |  |  |  |  |  |  |  |  |  |  |
Interest income (expense), net |  |  | — |  |  |  | (1,034 | ) |  |  | (1,034 | )
Other expense, net |  |  | — |  |  |  | (5,193 | ) |  |  | (5,193 | )
Income taxes |  |  | — |  |  |  | 1,559 |  |  |  | 1,559 |
Balance at September 30, 2019 |  | $ | (4,581 | ) |  | $ | — |  |  | $ | (4,581 | )

18

10. Revenue recognition and accounts receivable

Revenue Recognition

The Company has two reporting segments, which consist of Global Spine and Global Extremities. Within the Global Spine reporting segment there are three product categories: Bone Growth Therapies, Spinal Implants and Biologics.

The tables below present net sales by major product category by reporting segment:

|  | Three Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | Change |
Bone Growth Therapies |  | $ | 48,836 |  |  | $ | 48,059 |  |  |  | 1.6 | %
Spinal Implants |  |  | 22,947 |  |  |  | 22,102 |  |  |  | 3.8 | %
Biologics |  |  | 16,308 |  |  |  | 14,636 |  |  |  | 11.4 | %
Global Spine |  |  | 88,091 |  |  |  | 84,797 |  |  |  | 3.9 | %
Global Extremities |  |  | 25,408 |  |  |  | 26,911 |  |  |  | -5.6 | %
Net sales |  | $ | 113,499 |  |  | $ | 111,708 |  |  |  | 1.6 | %

|  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | Change |
Bone Growth Therapies |  | $ | 146,228 |  |  | $ | 142,433 |  |  |  | 2.7 | %
Spinal Implants |  |  | 69,076 |  |  |  | 66,689 |  |  |  | 3.6 | %
Biologics |  |  | 48,784 |  |  |  | 43,639 |  |  |  | 11.8 | %
Global Spine |  |  | 264,088 |  |  |  | 252,761 |  |  |  | 4.5 | %
Global Extremities |  |  | 74,373 |  |  |  | 79,203 |  |  |  | -6.1 | %
Net sales |  | $ | 338,461 |  |  | $ | 331,964 |  |  |  | 2.0 | %

Product Sales and Marketing Service Fees

The table below presents net sales, which includes product sales and marketing service fees, for the three and nine months ended September 30, 2019 and 2018.

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Product sales |  | $ | 97,833 |  |  | $ | 97,604 |  |  | $ | 291,632 |  |  | $ | 289,946 |
Marketing service fees |  |  | 15,666 |  |  |  | 14,104 |  |  |  | 46,829 |  |  |  | 42,018 |
Net sales |  | $ | 113,499 |  |  | $ | 111,708 |  |  | $ | 338,461 |  |  | $ | 331,964 |

Product sales primarily consist of the sale of bone growth therapy devices and internal and external fixation products. Marketing service fees are received from MTF Biologics based on total sales of biologics tissues and relate solely to the Global Spine reporting segment. Revenues exclude any value added or other local taxes, intercompany sales and trade discounts. Shipping and handling costs for products shipped to customers are included in cost of sales.

Puerto Rico Settlement

In June 2019, the Company received a payment of $1.4 million from the Administration of Medical Services of Puerto Rico, a government-owned corporation, in settlement of approximately $2.5 million of outstanding accounts receivable. This $2.5 million of outstanding accounts receivable had previously been fully reserved between the Company’s allowances for doubtful accounts and contractual allowances. As a result of this settlement, and in accordance with the Company’s policy, the Company recorded the resulting adjustment to contractual allowances of $0.4 million within net sales and the recovery of the allowance for doubtful accounts as a credit to bad debt expense of $1.0 million.

Other Contract Assets

The Company’s contract assets, excluding trade accounts receivable (“Other Contract Assets”), largely consist of payments made to certain distributors to obtain contracts, gain access to customers in certain territories, and to provide the benefit of the exclusive distribution of Orthofix products. Other Contract Assets are included in other long-term assets or other current assets, dependent

19

upon the original term of the related agreement, and totaled $3.5 million and $1.9 million as of September 30, 2 019, and December 31, 2018, respectively.

11. Business segment information

During the first quarter of 2019, the Company changed its reporting segments from four reporting segments, previously reported as Bone Growth Therapies, Spinal Implants, Biologics, and Orthofix Extremities, to two reporting segments: Global Spine and Global Extremities. Additionally, the Company changed the performance measure used to evaluate segment performance from Non-GAAP net margin to EBITDA. These changes were made to align how the chief operating decision maker manages the business, reviews operating performance and allocates resources. The Company has revised its segment reporting to represent how the business is now managed and restated prior periods to conform to the current segment presentation. Corporate activities are comprised of the operating expenses and activities of the Company not necessarily identifiable within the two reporting segments, such as human resources, finance, legal, and information technology functions.

As part of the change in reporting segments, the Company performed a quantitative assessment of goodwill immediately prior to and subsequently following the change in reporting segments. The analysis did not result in an impairment. In addition, the net carrying value of goodwill that was previously reported under the prior reporting segments (i) Bone Growth Therapies, (ii) Spinal Implants, and (iii) Biologics has been consolidated and is now included within the Global Spine reporting segment as of September 30, 2019.

As mentioned above, the primary metric used in managing the Company is EBITDA. The table below presents EBITDA by reporting segment:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Global Spine |  | $ | (6,033 | ) |  | $ | 15,637 |  |  | $ | 21,065 |  |  | $ | 53,492 |
Global Extremities |  |  | 1,229 |  |  |  | 3,357 |  |  |  | 3,806 |  |  |  | 7,173 |
Corporate |  |  | (15,949 | ) |  |  | (15,403 | ) |  |  | (38,356 | ) |  |  | (35,097 | )
Total EBITDA |  | $ | (20,753 | ) |  | $ | 3,591 |  |  | $ | (13,485 | ) |  | $ | 25,568 |
Depreciation and amortization |  |  | (6,275 | ) |  |  | (4,738 | ) |  |  | (18,180 | ) |  |  | (13,661 | )
Interest income (expense), net |  |  | 186 |  |  |  | (181 | ) |  |  | 386 |  |  |  | (615 | )
Income (loss) before income taxes |  | $ | (26,842 | ) |  | $ | (1,328 | ) |  | $ | (31,279 | ) |  | $ | 11,292 |

Geographical information

The table below presents net sales by geographic destination for each reporting unit and for the consolidated Company:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Global Spine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 82,816 |  |  | $ | 79,502 |  |  | $ | 246,943 |  |  | $ | 239,262 |
International |  |  | 5,275 |  |  |  | 5,295 |  |  |  | 17,145 |  |  | $ | 13,499 |
Total Global Spine |  |  | 88,091 |  |  |  | 84,797 |  |  |  | 264,088 |  |  |  | 252,761 |
Global Extremities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 6,636 |  |  |  | 7,254 |  |  |  | 20,078 |  |  |  | 21,193 |
International |  |  | 18,772 |  |  |  | 19,657 |  |  |  | 54,295 |  |  |  | 58,010 |
Total Global Extremities |  |  | 25,408 |  |  |  | 26,911 |  |  |  | 74,373 |  |  |  | 79,203 |
Consolidated |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  |  | 89,452 |  |  |  | 86,756 |  |  |  | 267,021 |  |  |  | 260,455 |
International |  |  | 24,047 |  |  |  | 24,952 |  |  |  | 71,440 |  |  |  | 71,509 |
Net sales |  | $ | 113,499 |  |  | $ | 111,708 |  |  | $ | 338,461 |  |  | $ | 331,964 |

20

12. Acquisition-related amortization and remeasurement

Acquisition-related amortization and remeasurement consists of amortization related to intangible assets acquired through business combinations or asset acquisitions and the remeasurement of any related contingent consideration arrangement. Components of acquisition-related amortization and remeasurement for the three months and nine months ended September 30, 2019 and 2018, respectively, are as follows:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Changes in fair value of contingent consideration |  | $ | 22,270 |  |  | $ | 1,580 |  |  | $ | 28,140 |  |  | $ | 2,689 |
Amortization of acquired intangibles |  |  | 1,338 |  |  |  | 429 |  |  |  | 3,733 |  |  |  | 802 |
Total |  | $ | 23,608 |  |  | $ | 2,009 |  |  | $ | 31,873 |  |  | $ | 3,491 |

13. Share-based compensation

The following tables present the detail of share-based compensation by line item in the condensed consolidated statements of operations and comprehensive income (loss) as well as by award type:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Cost of sales |  | $ | 169 |  |  | $ | 151 |  |  | $ | 536 |  |  | $ | 408 |
Sales and marketing |  |  | 583 |  |  |  | 514 |  |  |  | 1,885 |  |  |  | 1,436 |
General and administrative |  |  | 4,760 |  |  |  | 4,194 |  |  |  | 13,888 |  |  |  | 11,488 |
Research and development |  |  | 332 |  |  |  | 402 |  |  |  | 1,069 |  |  |  | 1,060 |
Total |  | $ | 5,844 |  |  | $ | 5,261 |  |  | $ | 17,378 |  |  | $ | 14,392 |

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Stock options |  | $ | 599 |  |  | $ | 579 |  |  | $ | 3,637 |  |  | $ | 2,442 |
Time-based restricted stock awards and units |  |  | 3,805 |  |  |  | 2,244 |  |  |  | 8,462 |  |  |  | 5,480 |
Performance-based restricted stock awards and units |  |  | — |  |  |  | 734 |  |  |  | — |  |  |  | 1,493 |
Market-based restricted stock units |  |  | 1,092 |  |  |  | 1,298 |  |  |  | 4,015 |  |  |  | 3,855 |
Stock purchase plan |  |  | 348 |  |  |  | 406 |  |  |  | 1,264 |  |  |  | 1,122 |
Total |  | $ | 5,844 |  |  | $ | 5,261 |  |  | $ | 17,378 |  |  | $ | 14,392 |

During the three months ended September 30, 2019 and 2018, the Company issued 43,603 and 50,928 shares, respectively, of common stock related to stock purchase plan issuances, stock option exercises and the vesting of restricted stock awards and units. During the nine months ended September 30, 2019 and 2018, the Company issued 295,496 and 257,833 shares, respectively, of common stock related to stock purchase plan issuances, stock option exercises and the vesting of restricted stock awards and units.

On August 5, 2019 the Company entered into an employment agreement with its new President of Global Spine and awarded restricted stock units and stock options valued at approximately $1.5 million as inducement grants.

Share-Based Compensation Modifications

During the first quarter of 2019, the Company entered into a Transition and Retirement Agreement (the “Retirement Agreement”) with the Company’s President and Chief Executive Officer. As part of the Retirement Agreement, certain time-based stock options and restricted stock awards were modified to accelerate the vesting to the retirement date. In addition, stock options were modified to extend the post-termination exercise period from 18 months under a standard qualified retirement to up to four years, dependent upon the remaining contractual term of the options. The Company recognized approximately $2.2 million and $5.9

21

million in share-based compensation expense during the three and nine months ended September 30, 2019, related to the R etirement Agreement, which was charged to general and administrative expense in the condensed consolidated statements of operations and comprehensive income (loss).

14. Income taxes

Income tax provisions for interim periods are based on an estimated annual income tax rate, adjusted for discrete tax items. As a result, the Company’s interim effective tax rates may vary significantly from the statutory tax rate and the annual effective tax rate.

For the three months ended September 30, 2019 and 2018, the effective tax rate was (50.9%) and 8.8%, respectively. For the nine months ended September 30, 2019 and 2018, the effective tax rate was (28.4%) and 56.3%, respectively. The primary factors affecting the Company’s effective tax rate for the three and nine months ended September 30, 2019, were financial expenses not deductible for tax purposes, primarily related to acquisition-related items, which includes remeasurement of contingent consideration, increased limitation of the deductibility of executive compensation, and benefits related to effective settlement of the 2015 federal tax examination and statute expirations.

During the first quarter of 2019, the Internal Revenue Service concluded an examination of the Company’s federal income tax return for 2015, which resulted in a benefit of $1.8 million. The Company believes it is reasonably possible that, in the next 12 months, the amount of unrecognized tax benefits related to the resolution of federal, state and foreign matters could be reduced by $13.0 million to $13.4 million as audits close and statutes expire.

15. Earnings per share (“EPS”)

The Company uses the two-class method of computing basic EPS due to the existence of non-vested restricted stock awards with nonforfeitable rights to dividends or dividend equivalents (referred to as participating securities). For the three and nine months ended September 30, 2019 and 2018, no significant adjustments were made to net income for purposes of calculating basic and diluted EPS. The following is a reconciliation of the weighted average shares used in diluted EPS computations.

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Weighted average common shares-basic |  |  | 18,957,876 |  |  |  | 18,562,204 |  |  |  | 18,847,728 |  |  |  | 18,460,848 |
Effect of dilutive securities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Unexercised stock options and stock purchase plan |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 312,320 |
Unvested restricted stock awards and units |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 91,001 |
Weighted average common shares-diluted |  |  | 18,957,876 |  |  |  | 18,562,204 |  |  |  | 18,847,728 |  |  |  | 18,864,169 |

There were 1,814,544 and 2,088,843 weighted average outstanding stock options and restricted stock awards and units not included in the diluted EPS computation for the three months ended September 30, 2019 and 2018, respectively, and 1,880,423 and 359,172 weighted average outstanding stock options and restricted stock awards and units not included in the diluted EPS computation for the nine months ended September 30, 2019 and 2018, respectively, because inclusion of these awards was anti-dilutive or, for performance-based and market-based restricted stock awards and units, all necessary conditions had not been satisfied by the end of the respective period.

22

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of Orthofix Medical Inc.’s (sometimes referred to as “we,” “us” or “our”) financial condition and results of our operations should be read in conjunction with the “Forward-Looking Statements” and our condensed consolidated financial statements and related notes thereto appearing elsewhere in this Form 10-Q.

Executive Summary

We are a global medical device company focused on musculoskeletal products and therapies. Headquartered in Lewisville, Texas, we have two reporting segments: Global Spine and Global Extremities. Our products are widely distributed by our sales representatives and distributors.

Notable highlights and achievements in the third quarter of 2019 include the following:

| • | Net sales were $113.5 million, an increase of 1.6% on a reported basis and 2.5% on a constant currency basis

| • | Biologics tissue service fees increased 11.4%, its second consecutive quarter of double-digit growth

| • | Net loss was $40.5 million, a decrease of $39.3 million compared to the prior year period

| • | Decrease in earnings before interest, income taxes, depreciation, and amortization (“EBITDA”) of $24.3 million, largely driven by expenses recognized during the third quarter of 2019 for acquisition-related remeasurement

Results of Operations

The following table provides certain items in our condensed consolidated statements of operations and comprehensive income (loss) as a percent of net sales:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2019 (%) |  |  | 2018 (%) |  |  | 2019 (%) |  |  | 2018 (%) |
Net sales |  |  | 100.0 |  |  |  | 100.0 |  |  |  | 100.0 |  |  |  | 100.0 |
Cost of sales |  |  | 21.9 |  |  |  | 21.5 |  |  |  | 22.0 |  |  |  | 21.4 |
Gross profit |  |  | 78.1 |  |  |  | 78.5 |  |  |  | 78.0 |  |  |  | 78.6 |
Sales and marketing |  |  | 48.3 |  |  |  | 44.7 |  |  |  | 48.9 |  |  |  | 45.7 |
General and administrative |  |  | 18.6 |  |  |  | 19.9 |  |  |  | 18.8 |  |  |  | 19.2 |
Research and development |  |  | 7.0 |  |  |  | 8.6 |  |  |  | 7.7 |  |  |  | 7.4 |
Acquisition-related amortization and remeasurement |  |  | 20.8 |  |  |  | 1.8 |  |  |  | 9.4 |  |  |  | 1.0 |
Operating income (loss) |  |  | (16.6 | ) |  |  | 3.5 |  |  |  | (6.8 | ) |  |  | 5.3 |
Net income (loss) |  |  | (35.7 | ) |  |  | (1.1 | ) |  |  | (11.9 | ) |  |  | 1.5 |

Net Sales by Product Category and Reporting Segment

The following tables provide net sales by major product category by reporting segment:

|  | Three Months Ended September 30, |  |  | Percentage Change |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | Reported |  |  | Constant Currency |
Bone Growth Therapies |  | $ | 48,836 |  |  | $ | 48,059 |  |  |  | 1.6 | % |  |  | 1.6 | %
Spinal Implants |  |  | 22,947 |  |  |  | 22,102 |  |  |  | 3.8 | % |  |  | 4.4 | %
Biologics |  |  | 16,308 |  |  |  | 14,636 |  |  |  | 11.4 | % |  |  | 11.4 | %
Global Spine |  |  | 88,091 |  |  |  | 84,797 |  |  |  | 3.9 | % |  |  | 4.0 | %
Global Extremities |  |  | 25,408 |  |  |  | 26,911 |  |  |  | -5.6 | % |  |  | -2.4 | %
Net sales |  | $ | 113,499 |  |  | $ | 111,708 |  |  |  | 1.6 | % |  |  | 2.5 | %

23

|  | Nine Months Ended September 30, |  |  | Percentage Change |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | Reported |  |  | Constant Currency |
Bone Growth Therapies |  | $ | 146,228 |  |  | $ | 142,433 |  |  |  | 2.7 | % |  |  | 2.7 | %
Spinal Implants |  |  | 69,076 |  |  |  | 66,689 |  |  |  | 3.6 | % |  |  | 4.3 | %
Biologics |  |  | 48,784 |  |  |  | 43,639 |  |  |  | 11.8 | % |  |  | 11.8 | %
Global Spine |  |  | 264,088 |  |  |  | 252,761 |  |  |  | 4.5 | % |  |  | 4.7 | %
Global Extremities |  |  | 74,373 |  |  |  | 79,203 |  |  |  | -6.1 | % |  |  | -1.8 | %
Net sales |  | $ | 338,461 |  |  | $ | 331,964 |  |  |  | 2.0 | % |  |  | 3.1 | %

Global Spine

Global Spine offers the following products categories:

| - | Bone Growth Therapies, which manufactures, distributes, sells, and provides support services for market leading devices that enhance bone fusion. Bone Growth Therapies uses distributors and sales representatives to sell its devices and provide associated services to hospitals, healthcare providers, and patients.

| - | Spinal Implants, which designs, develops and markets a broad portfolio of motion preservation and implant products used in surgical procedures of the spine. Spinal Implants distributes its products globally through a network of distributors and sales representatives to sell spine products to hospitals and healthcare providers.

| - | Biologics, which provides a portfolio of regenerative products and tissue forms that allow physicians to successfully treat a variety of spinal and orthopedic conditions. Biologics markets its tissues to hospitals and healthcare providers, primarily in the U.S., through a network of employed and independent sales representatives.

Three months ended September 30, 2019 compared to 2018

Net sales increased $3.3 million or 3.9%

| • | Bone Growth Therapies net sales increased $0.8 million or 1.6%, primarily driven by an increase in order volume in the quarter, partially offset by customer sales mix and product mix changes

| • | Spinal Implants net sales increased $0.8 million or 3.8%, primarily due to a $1.4 million increase in Motion Preservation due to our launch of the M6 artificial cervical disc in the U.S. and partially offset by timing in international stocking orders for legacy Spine Fixation products

| • | Biologics net sales increased $1.7 million or 11.4%, primarily due to distribution added during the last year and the return to solid results in each of the three U.S. sales regions, as volume increased related to Trinity tissues by 14.0%, partially offset by a low single-digit price decline

Nine months ended September 30, 2019 compared to 2018

Net sales increased $11.3 million or 4.5%

| • | Bone Growth Therapies net sales increased $3.8 million or 2.7%, primarily driven by an increase in order volume, partially offset by customer sales mix and product mix changes

| • | Spinal Implants net sales increased $2.4 million or 3.6%, primarily driven by an increase of $5.3 million in Motion Preservation sales as we acquired Spinal Kinetics during the second quarter of 2018, and partially offset by a decrease in legacy Spine Fixation sales of $2.9 million, primarily resulting from disruptions in our U.S. distribution channel as we upgrade our legacy sales force with new, high-potential sales partners

| • | Biologics net sales increased $5.1 million or 11.8%, primarily due to distribution added during the last year and the return to solid results in each of the three U.S. sales regions, as volume increased related to Trinity tissues by 16.9%, partially offset by a low single-digit price decline as well as a contractual reduction in the marketing services fee we receive from MTF Biologics, which became effective during the first quarter of 2018

24

Global Extremities

Global Extremities offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. Global Extremities distributes its products globally through a network of distributors and sales representatives to sell orthopedic products to hospitals and health providers.

Three months ended September 30, 2019 compared to 2018

Net sales decreased $1.5 million or 5.6%

| • | Decrease of $0.9 million due to the changes in foreign currency exchange rates, which had a negative impact on net sales

| • | Decrease of $0.6 million largely attributed to variability in the timing of orders from our international stocking distributors and growth in our global direct-sales markets

Nine months ended September 30, 2019 compared to 2018

Net sales decreased $4.8 million or 6.1%

| • | Decrease of $3.4 million due to the changes in foreign currency exchange rates, which had a negative impact on net sales

| • | Decrease of $1.4 million largely attributed to variability in the timing of orders from our international stocking distributors and growth in our global direct-sales markets

Gross Profit

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | % Change |  |  | 2019 |  |  | 2018 |  |  | % Change |
Net sales |  | $ | 113,499 |  |  | $ | 111,708 |  |  |  | 1.6 | % |  | $ | 338,461 |  |  | $ | 331,964 |  |  |  | 2.0 | %
Cost of sales |  |  | 24,896 |  |  |  | 24,020 |  |  |  | 3.6 | % |  |  | 74,416 |  |  |  | 71,002 |  |  |  | 4.8 | %
Gross profit |  | $ | 88,603 |  |  | $ | 87,688 |  |  |  | 1.0 | % |  | $ | 264,045 |  |  | $ | 260,962 |  |  |  | 1.2 | %
Gross margin |  |  | 78.1 | % |  |  | 78.5 | % |  |  | -0.4 | % |  |  | 78.0 | % |  |  | 78.6 | % |  |  | -0.6 | %

Three months ended September 30, 2019 compared to 2018

Gross profit increased $0.9 million

| • | Increase primarily due to the growth in net sales and partially offset by a decrease in gross margin, which decreased slightly to 78.1% compared to 78.5% in the prior year period

Nine months ended September 30, 2019 compared to 2018

Gross profit increased $3.1 million

| • | Increase primarily due to the growth in net sales and partially offset by a decrease in gross margin, which decreased to 78.0% compared to 78.6% in the prior year period

| • | Decrease in gross margin largely due to higher than normal charges related to the buildup of Spinal Implants inventory to support sales growth from our new sales partners in key geographies

Sales and Marketing Expense

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | % Change |  |  | 2019 |  |  | 2018 |  |  | % Change |
Sales and marketing |  | $ | 54,805 |  |  | $ | 49,898 |  |  |  | 9.8 | % |  | $ | 165,363 |  |  | $ | 151,695 |  |  |  | 9.0 | %
As a percentage of net sales |  |  | 48.3 | % |  |  | 44.7 | % |  |  | 3.6 | % |  |  | 48.9 | % |  |  | 45.7 | % |  |  | 3.2 | %

25

Three months ended September 30, 2019 compared to 2018

Sales and marketing expense increased $4.9 million

| • | Increase largely attributable to increases in headcount, training and education costs, and increased marketing efforts to support growth and the launch of the M6-C artificial cervical disc in the U.S.

| • | Further increases relate to higher variable compensation rates in our Global Spine segment to support growth

Nine months ended September 30, 2019 compared to 2018

Sales and marketing expense increased $13.7 million

| • | Increase largely attributable to increases in headcount, training and education costs, and increased marketing efforts to support growth and the launch of the M6-C artificial cervical disc in the U.S.

| • | Further increases relate to higher variable compensation rates in our Global Spine segment to support growth

General and Administrative Expense

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | % Change |  |  | 2019 |  |  | 2018 |  |  | % Change |
General and administrative |  | $ | 21,090 |  |  | $ | 22,276 |  |  |  | -5.3 | % |  | $ | 63,497 |  |  | $ | 63,658 |  |  |  | -0.3 | %
As a percentage of net sales |  |  | 18.6 | % |  |  | 19.9 | % |  |  | -1.3 | % |  |  | 18.8 | % |  |  | 19.2 | % |  |  | -0.4 | %

Three months ended September 30, 2019 compared to 2018

General and administrative expense decreased by $1.2 million

| • | Decrease of $1.6 million in expenses associated with strategic investments, largely due to diligence and integration costs related to the acquisition of Spinal Kinetics and expenses associated with our change in jurisdiction of organization from Curaçao to the State of Delaware (the “Domestication”) in 2018

| • | Decrease of $1.3 million in certain compensation expenses, excluding the impact of succession charges

| • | Partially offset by an increase of $1.2 million attributable to transition and succession charges, including acceleration of certain share-based compensation expense, relating to retirement, transition, or termination of certain named executive officers

| • | Further offset by an increase of $0.4 million in depreciation expense

Nine months ended September 30, 2019 compared to 2018

General and administrative expense decreased by $0.2 million

| • | Decrease of $3.3 million in expenses associated with strategic investments, largely due to diligence and integration costs related to the acquisition of Spinal Kinetics and expenses associated with the Domestication in 2018

| • | Decrease of $3.3 million in certain compensation expenses, such as share-based compensation expense, excluding the impact of succession charges

| • | Partially offset by an increase of $5.2 million attributable to transition and succession charges, including acceleration of certain share-based compensation expense, relating to retirement, transition, or termination of certain named executive officers

| • | Further offset by an increase of $1.3 million in depreciation expense

Research and Development Expense

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | % Change |  |  | 2019 |  |  | 2018 |  |  | % Change |
Research and development |  | $ | 7,982 |  |  | $ | 9,598 |  |  |  | -16.8 | % |  | $ | 26,191 |  |  | $ | 24,426 |  |  |  | 7.2 | %
As a percentage of net sales |  |  | 7.0 | % |  |  | 8.6 | % |  |  | -1.6 | % |  |  | 7.7 | % |  |  | 7.4 | % |  |  | 0.3 | %

26

Three months ended September 30, 2019 compared to 2018

Research and development expense decreased by $1.6 million

| • | Decrease primarily due to higher regulatory spending in the third quarter of 2018 associated with the premarket approval process for the M6-C Cervical Disc, which was approved by the U.S. Food and Drug Administration (“FDA”) in February of 2019

Nine months ended September 30, 2019 compared to 2018

Research and development expense increased $1.8 million

| • | Increase largely attributable to the Spinal Kinetics acquisition, which was acquired during the second quarter of 2018, and the regulatory efforts associated with the FDA premarket approval of the M6-C Cervical Disc, which was obtained in February of 2019

| • | Increase also related to costs to comply with recent medical device reporting regulations in the European Union

Acquisition-related Amortization and Remeasurement

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | % Change |  |  | 2019 |  |  | 2018 |  |  | % Change |
Acquisition-related amortization and remeasurement |  | $ | 23,608 |  |  | $ | 2,009 |  |  |  | 1075.1 | % |  | $ | 31,873 |  |  | $ | 3,491 |  |  |  | 813.0 | %
As a percentage of net sales |  |  | 20.8 | % |  |  | 1.8 | % |  |  | 19.0 | % |  |  | 9.4 | % |  |  | 1.0 | % |  |  | 8.4 | %

Acquisition-related amortization and remeasurement consists of amortization related to intangibles acquired through business combinations or asset acquisitions and the remeasurement of any related contingent consideration arrangement.

Three months ended September 30, 2019 compared to 2018

Acquisition-related amortization and remeasurement increased $21.6 million

| • | Increase of $20.7 million related to the remeasurement of potential future revenue-based milestone payments associated with the Spinal Kinetics acquisition that become due upon achievement of certain revenue targets

| • | Increase of $0.9 million related to the amortization of intangible assets acquired through business combinations or asset acquisitions; of this amount, $0.7 million is attributable to the Spinal Kinetics acquisition, which occurred during the second quarter of 2018 and includes amortization of acquired in-process research and development costs following achievement of the FDA approval milestone during the first quarter of 2019

Nine months ended September 30, 2019 compared to 2018

Acquisition-related amortization and remeasurement increased $28.4 million

| • | Increase of $24.0 million related to the remeasurement of potential future revenue-based milestone payments associated with the Spinal Kinetics acquisition that become due upon achievement of certain revenue targets

| • | Increase of $1.5 million related to the remeasurement of the FDA milestone associated with the Spinal Kinetics acquisition, which was achieved and paid during the first quarter of 2019

| • | Increase of $2.9 million related to the amortization of intangible assets acquired through business combinations or asset acquisitions; of this amount, $2.2 million is attributable to the Spinal Kinetics acquisition, which occurred during the second quarter of 2018 and includes amortization of acquired in-process research and development costs following achievement of the FDA milestone during the first quarter of 2019

27

Non-operating Income and Expense

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | % Change |  |  | 2019 |  |  | 2018 |  |  | % Change |
Interest income (expense), net |  | $ | 186 |  |  | $ | (181 | ) |  |  | -202.8 | % |  | $ | 386 |  |  | $ | (615 | ) |  |  | -162.8 | %
Other expense, net |  |  | (8,146 | ) |  |  | (5,054 | ) |  |  | 61.2 | % |  |  | (8,786 | ) |  |  | (5,785 | ) |  |  | 51.9 | %

Three months ended September 30, 2019 compared to 2018

Other income (expense), net, decreased $3.1 million

| • | Decrease of $6.5 million associated with an other-than-temporary impairment on the eNeura debt security during the third quarter of 2019

| • | Decrease of $1.0 million associated with changes in foreign currency rates, as we recorded a non-cash remeasurement loss of $1.6 million in the third quarter of 2019 compared to a loss of $0.6 million in the third quarter of 2018

| • | Partially offset by an increase of $4.4 million due to the impairment of our equity holdings and warrants in Bone Biologics, Inc. (“Bone Biologics”) common stock during the third quarter of 2018

Nine months ended September 30, 2019 compared to 2018

Other income (expense), net, decreased $3.0 million

| • | Decrease of $6.5 million associated with an other-than-temporary impairment on the eNeura debt security during the third quarter of 2019

| • | Partially offset by a net increase of $3.1 million relating to changes in fair value and impairments of our equity holdings and warrants in Bone Biologics common stock during 2018

| • | Further offset by an increase of $0.6 million associated with changes in foreign currency rates, as we recorded a non-cash remeasurement loss of $2.2 million in the nine months ended September 30, 2019 compared to a loss of $2.8 million in the nine months ended September 30, 2018

Income Taxes

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | % Change |  |  | 2019 |  |  | 2018 |  |  | % Change |
Income tax expense (benefit) |  | $ | 13,656 |  |  | $ | (117 | ) |  |  | -11771.8 | % |  | $ | 8,869 |  |  | $ | 6,352 |  |  |  | 39.6 | %
Effective tax rate |  |  | -50.9 | % |  |  | 8.8 | % |  |  | -59.7 | % |  |  | -28.4 | % |  |  | 56.3 | % |  |  | -84.7 | %

Three months ended September 30, 2019 compared to 2018

The decrease in the effective tax compared to the prior year period rate was primarily a result of the following factors:

| • | Decrease in pre-tax earnings

| • | Increases in financial expenses not deductible for tax purposes, primarily related to acquisition-related remeasurement

| • | Increases in non-deductible executive compensation due to provisions of the Tax Cuts and Jobs Act (the “Tax Act”)

The primary factors affecting our effective tax rate for the third quarter of 2019 are as follows:

| • | Financial expenses not deductible for tax purposes, primarily related to acquisition-related remeasurement

| • | Non-deductible executive compensation due to provisions of the Tax Act

Nine months ended September 30, 2019 compared to 2018

The decrease in the effective tax rate compared to the prior year period was primarily a result of the following factors:

| • | Decrease in pre-tax earnings

| • | Increases in financial expenses not deductible for tax purposes, primarily related to acquisition-related remeasurement

| • | Increases in non-deductible executive compensation due to provisions of the Tax Act

| • | Benefits related to effective settlement of the 2015 IRS exam and statute expirations

28

The primary factors affecting our effective tax rate for the nine months ended September 30, 2019 are as follows:

| • | Financial expenses not deductible for tax purposes, primarily related to acquisition-related remeasurement

| • | Non-deductible executive compensation due to provisions of the Tax Act

| • | Benefits related to effective settlement of the 2015 IRS exam and statute expirations

Segment Review

As discussed above, we changed the performance measure used to evaluate segment performance from Non-GAAP net margin to EBITDA during the first quarter of 2019. When compared to the prior year period, EBITDA decreased $24.3 million for the three months ended September 30, 2019 and decreased $39.1 million for the nine months ended September 30, 2019. These changes are largely driven by the fluctuations discussed above, but are primarily attributable to changes in acquisition-related amortization and remeasurement and sales and marketing expense. The following table reconciles EBITDA to income (loss) before income taxes:

|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Global Spine |  | $ | (6,033 | ) |  | $ | 15,637 |  |  | $ | 21,065 |  |  | $ | 53,492 |
Global Extremities |  |  | 1,229 |  |  |  | 3,357 |  |  |  | 3,806 |  |  |  | 7,173 |
Corporate |  |  | (15,949 | ) |  |  | (15,403 | ) |  |  | (38,356 | ) |  |  | (35,097 | )
Total EBITDA |  | $ | (20,753 | ) |  | $ | 3,591 |  |  | $ | (13,485 | ) |  | $ | 25,568 |
Depreciation and amortization |  |  | (6,275 | ) |  |  | (4,738 | ) |  |  | (18,180 | ) |  |  | (13,661 | )
Interest income (expense), net |  |  | 186 |  |  |  | (181 | ) |  |  | 386 |  |  |  | (615 | )
Income (loss) before income taxes |  | $ | (26,842 | ) |  | $ | (1,328 | ) |  | $ | (31,279 | ) |  | $ | 11,292 |

Liquidity and Capital Resources

Cash, cash equivalents, and restricted cash at September 30, 2019, totaled $57.5 million compared to $72.2 million at December 31, 2018, with the decrease largely a result of $15.0 million in cash paid in connection with achievement of the Spinal Kinetics FDA Milestone in 2019.

|  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | Change |
Net cash from operating activities |  | $ | 20,090 |  |  | $ | 28,829 |  |  | $ | (8,739 | )
Net cash from investing activities |  |  | (21,281 | ) |  |  | (55,921 | ) |  |  | 34,640 |
Net cash from financing activities |  |  | (12,610 | ) |  |  | 2,988 |  |  |  | (15,598 | )
Effect of exchange rate changes on cash |  |  | (885 | ) |  |  | (811 | ) |  |  | (74 | )
Net change in cash, cash equivalents and restricted cash |  | $ | (14,686 | ) |  | $ | (24,915 | ) |  | $ | 10,229 |

The following table presents free cash flow, a non-GAAP financial measure, which is calculated by subtracting capital expenditures from net cash from operating activities.

|  | Nine Months Ended September 30, |
(U.S. Dollars, in thousands) |  | 2019 |  |  | 2018 |  |  | Change |
Net cash from operating activities |  | $ | 20,090 |  |  | $ | 28,829 |  |  | $ | (8,739 | )
Capital expenditures |  |  | (14,881 | ) |  |  | (10,724 | ) |  |  | (4,157 | )
Free cash flow |  | $ | 5,209 |  |  | $ | 18,105 |  |  | $ | (12,896 | )

29

Operating Activities

Cash flows from operating activities decreased $8.7 million

| • | Decrease in net income of $45.1 million

| • | Net increase of $40.3 million for non-cash gains and losses, largely related to changes in fair value of contingent consideration, depreciation and amortization, share-based compensation expense, and non-cash interest and losses on the valuation of investment securities

| • | Net decrease of $3.9 million relating to changes in working capital accounts, primarily attributable to changes in inventories, other current liabilities, and other long-term assets and liabilities

Two of our primary working capital accounts are accounts receivable and inventory. Days sales in receivables were 65 days at September 30, 2019 compared to 61 days at September 30, 2018. Inventory turns remained consistent at 1.2 times as of September 30, 2019 and 2018.

Investing Activities

Cash flows from investing activities increased $34.6 million

| • | Increase of $43.7 million associated with cash paid in relation to the Spinal Kinetics acquisition in 2018, net of cash acquired

| • | Increase of $0.9 million associated with the acquisition of certain intangible assets in a transaction with a former distributor and by our additional investment of $0.5 million in Bone Biologics during the first quarter of 2018

| • | Partially offset by $6.4 million associated with cash paid in relation to the acquisition of certain assets of Options Medical, one of our former distributors, during the first quarter of 2019

| • | Further offset by $4.2 million attributable to increased capital expenditures compared to the prior year

Financing Activities

Cash flows from financing activities decreased $15.6 million

| • | Decrease of $13.7 million associated with our payment of the FDA Milestone associated with the Spinal Kinetics acquisition during the first quarter of 2019, which represents the acquisition-date fair value attributable to the FDA Milestone liability originally recognized

| • | Decrease in net proceeds of $0.9 million from the issuance of common shares

| • | Decrease of $0.3 million attributable to principal payments made during 2019 relating to our finance lease and $0.7 million attributable to other financing cash flows, which primarily relate to deferred payments made associated with the acquisition of certain intangible assets in transactions with former distributors

Credit Facilities

On October 25, 2019, we entered into a Second Amended and Restated Credit Agreement (the “Amended Credit Agreement”) with JPMorgan Chase Bank, N.A. (“JPMorgan”), as Administrative Agent, and certain lender parties thereto. The Amended Credit Agreement provides for a $300 million secured revolving credit facility maturing on October 25, 2024 (the “Facility”), and amends and restates the existing $125 million secured revolving credit facility. As of October 28, 2019, we have not made any borrowings under the Amended Credit Agreement.

Borrowings under the Amended Credit Agreement may be used for, among other things, working capital and other general corporate purposes (including permitted acquisitions and permitted payments of dividends and other distributions). For information regarding the Amended Credit Agreement, see Note 6 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.

Other

For information regarding Contingencies, see Note 8 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein.

Spinal Kinetics Acquisition

As part of the consideration for the Spinal Kinetics acquisition, we agreed to milestone payments in the future of up to $60.0 million in cash. One milestone payment was for $15.0 million upon FDA approval of Spinal Kinetics’ M6-C artificial cervical disc (the “FDA Milestone”). During the first quarter of 2019, we obtained FDA approval of the M6-C artificial cervical disc for patients suffering

30

from cervical disease degeneration and the FDA Milestone payment was triggered. We paid the $15.0 million FDA Mi lestone payment on February 14, 2019 from cash on hand.

Two other milestone payments are comprised of revenue-based milestone payments of up to $45.0 million in connection with future sales of the M6-C artificial cervical disc and the M6-L artificial lumbar disc. The fair value of the contingent consideration arrangement as of September 30, 2019 was $41.7 million; however, the actual amount ultimately paid could be higher or lower than the fair value of the contingent consideration. At September 30, 2019, we classified $14.5 million of the liability attributable to the revenue-based milestones within other current liabilities, as we expect to pay one of the revenue-based milestones in the next twelve months, and the remaining $27.2 million within other long-term liabilities. For additional discussion of this matter, see Note 7 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

eNeura debt security

As of September 30, 2019, we held a debt security of eNeura, Inc. (“eNeura”), a privately held medical technology company that is developing devices for the treatment of migraines. The debt security was originally set to mature on March 4, 2019. On March 1, 2019, we entered into an Amended and Restated Senior Secured Promissory Note with eNeura (the “Restructured Debt Security”) to restructure the debt security, which extended the maturity date to the earlier of (i) March 4, 2022, (ii) the effective date of a change in control, or (iii) the effective date of an initial public offering by eNeura. As consideration for the extension, eNeura issued to us a Warrant to Purchase Common Stock (the “Warrant”), exercisable at $0.01 per share over a ten year contractual term, for a number of shares equal to 10% of the sum of the outstanding principal and accrued interest on the Amended and Restated Debt Security as of March 1, 2019, divided by $1.00 (subject to certain anti-dilution provisions).

We considered the restructuring of the eNeura debt security to be a Troubled Debt Restructuring (“TDR”). A TDR exists when a creditor for economic or legal reasons related to the debtor’s financial difficulties grants a concession to the debtor that it would not otherwise consider. In making this determination, we considered eNeura’s current financial condition and whether the restructuring of the debt security resulted in the granting of a concession after taking into account all the facts and circumstances surrounding the restructuring. The restructuring was undertaken to improve the likelihood of our effort to recover the investment in the original debt security.

Subsequent to the restructuring, the Restructured Debt Security was no longer accounted for at fair value, but rather in accordance with the accounting required for TDRs. The fair value of the debt security immediately prior to the restructuring was reclassified to be the carrying amount of the debt security, as such amount approximated our estimate of future cash collections discounted using the debt security’s effective interest rate of 8%. Our estimate of future cash flows involved significant judgment regarding the timing, expected events, and amount of future cash collections. Interest income on the restructured eNeura debt security was recorded using the interest income method; therefore, the amortized cost basis was accreted up to the amount of expected future cash flows over the term of the Restructured Debt Security.

During the quarter ended September 30, 2019, we engaged in negotiations with eNeura to settle the Restructured Debt Security and on October 25, 2019, we settled the Restructured Debt Security for a $4.0 million cash payment and agreed to transfer the Warrant to eNeura. As such, at September 30, 2019, we determined the Restructured Debt Security and Warrant were impaired and adjusted the carrying value of the Restructured Debt Security to $4.0 million, its settlement value, by recording a net other-than-temporary impairment of $6.5 million in other expense, net, which includes a reclassification of the related unrealized gains included in accumulated other comprehensive income of $5.2 million.

Brazil

On April 3, 2019, our appeal regarding the freezing of our local bank accounts in Brazil was heard by the Brazil Federal Court of Appeals of Rio de Janeiro, in which the Court ordered the unfreezing of the cash. Approximately $2.5 million was then returned without any restrictions in April 2019. As such, this balance has been reclassified to cash and cash equivalents as of September 30, 2019.

In September 2019, in relation to an ongoing legal dispute with a former Brazilian distributor, approximately $0.7 million of our cash in Brazil was frozen upon request to satisfy a judgment. Although we are appealing the judgment, this cash has been reclassified to restricted cash.

For additional discussion regarding these matters, see Note 8 of the Notes to the Unaudited Condensed Consolidated Financial Statements.

31

Off-balance Sheet Arrangements

As of September 30, 2019, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, cash flows, liquidity, capital expenditures or capital resources that are material to investors.

Contractual Obligations

There have been no material changes in any of our material contractual obligations as disclosed in our Form 10-K for the year ended December 31, 2018.

Critical Accounting Estimates

Our discussion of operating results is based upon the condensed consolidated financial statements and accompanying notes. The preparation of these statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Our critical accounting estimates are detailed in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no significant changes to our critical accounting estimates except for the following:

Leases

On January 1, 2019, we adopted ASU 2016-02, Leases (Topic 842). We determine if an arrangement is a lease at inception. Lease assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, our incremental borrowing rate is used as a discount rate, based on the information available at the commencement date, in determining the present value of lease payments. Lease assets also include the impact of any prepayments made and are reduced by impact of any lease incentives. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

We have made a policy election for all classifications of leases to combine lease and nonlease components and to account for them as a single lease component. Variable lease payments are excluded from the lease liability and recognized in the period in which the obligation is incurred.

Recently Issued Accounting Pronouncements

See Note 2 of the Notes to the Unaudited Condensed Consolidated Financial Statements for detailed information regarding the status of recently issued accounting pronouncements.

Non-GAAP Financial Measures

We believe that providing non-GAAP financial measures that exclude certain items provides investors with greater transparency to the information used by senior management in its financial and operational decision-making. We believe it is important to provide investors with the same non-GAAP metrics used to supplement information regarding the performance and underlying trends of our business operations in order to facilitate comparisons to historical operating results and internally evaluate the effectiveness of the our operating strategies. Disclosure of these non-GAAP financial measures also facilitates comparisons of our underlying operating performance with other companies in the industry that also supplement their GAAP results with non-GAAP financial measures.

The non-GAAP financial measures used in this filing may have limitations as analytical tools, and should not be considered in isolation or as a replacement for GAAP financial measures. Some of the limitations associated with the use of these non-GAAP financial measures are that they exclude items that reflect an economic cost that can have a material effect on cash flows.

32

Constant Currency

Constant currency is calculated by using foreign currency rates from the comparable, prior-year period, to present net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is most commonly used by management to analyze net sales without the impact of changes in foreign currency rates.

EBITDA

EBITDA is a non-GAAP metric defined as earnings before interest income (expense), income taxes, depreciation, and amortization. EBITDA is the primary metric used by our Chief Operating Decision Maker in managing the business.

Free Cash Flow

Free cash flow is calculated by subtracting capital expenditures from net cash from operating activities. Free cash flow is an important indicator of how much cash is generated or used by our normal business operations, including capital expenditures. Management uses free cash flow as a measure of progress on its capital efficiency and cash flow initiatives.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes to our market risks as disclosed in our Form 10-K for the year ended December 31, 2018.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) designed to provide reasonable assurance that the information required to be disclosed in reports filed or submitted under the Exchange Act are recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. These include controls and procedures designed to ensure that this information is accumulated and communicated to management, including our President and Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Management, with the participation of the President and Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2019. Based on this evaluation, our President and Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2019.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting, known to the President and Chief Executive Officer or the Chief Financial Officer that occurred for the quarterly period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

33

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

For information regarding legal proceedings, see Note 8 to the Notes to the Unaudited Condensed Consolidated Financial Statements contained herein, which is incorporated by reference into this Part II, Item 1.

Item 1A. Risk Factors

There have been no material changes to the risk factors disclosed in the “Risk Factors” section of our Form 10-K for the year ended December 31, 2018.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

We have not made any repurchases of our common stock during the third quarter of 2019.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

There are no matters to be reported under this heading.

34

Item 6. E xhibits

10.1 |  | Letter agreement, dated July 30, 2019, between the Company and Jon Serbousek (filed as an exhibit to the Company’s Current Report on Form 8-K filed on August 2, 2019 and incorporated herein by reference).
10.2* |  | Change in Control and Severance Agreement, dated August 5, 2019, between Jon Serbousek and Orthofix Medical Inc.
10.3* |  | Indemnification Agreement, dated August 5, 2019, between Jon C. Serbousek and Orthofix Medical Inc.
10.4 |  | Employee Inducement Non-Qualified Stock Option Agreement for Jon Serbousek (filed as an exhibit to the Company’s Form S-8 filed on August 5, 2019 and incorporated herein by reference).
10.5 |  | Employee Inducement Restricted Stock Unit Agreement for Jon Serbousek (filed as an exhibit to the Company’s Form S-8 filed on August 5, 2019 and incorporated herein by reference).
10.6 |  | Consulting Agreement, dated July 15, 2019, between Bradley V. Niemann and Orthofix Medical Inc. (filed as an exhibit to the Company’s Current Report on Form 8-K filed on July 15, 2019 and incorporated herein by reference).
31.1* |  | Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
31.2* |  | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
32.1* |  | Section 1350 Certifications of each of the Chief Executive Officer and Chief Financial Officer.
101.INS* |  | Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).
101.SCH* |  | Inline XBRL Taxonomy Extension Schema Document.
101.CAL* |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF* |  | Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB* |  | Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE* |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104* |  | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

* | Filed herewith.

35

SIGNAT URES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

| ORTHOFIX MEDICAL INC.
Date: October 28, 2019 | By: |  | /s/ BRADLEY R. MASON
| Name: |  | Bradley R. Mason
| Title: |  | President and Chief Executive Officer
Date: October 28, 2019 | By: |  | /s/ DOUG RICE
| Name: |  | Doug Rice
| Title: |  | Chief Financial Officer

36